Cover
Cover - shares | 9 Months Ended | |
Sep. 30, 2022 | Nov. 03, 2022 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Transition Report | false | |
Document Period End Date | Sep. 30, 2022 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2022 | |
Current Fiscal Year End Date | --12-31 | |
Document Quarterly Report | true | |
Entity File Number | 001-39871 | |
Entity Registrant Name | SAB BIOTHERAPEUTICS, INC. | |
Entity Central Index Key | 0001833214 | |
Entity Tax Identification Number | 85-3899721 | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, Address Line One | 2100 East 54th Street North | |
Entity Address, City or Town | Sioux Falls | |
Entity Address, State or Province | SD | |
Entity Address, Postal Zip Code | 57104 | |
City Area Code | 605 | |
Local Phone Number | 679-6980 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Elected Not To Use the Extended Transition Period | false | |
Entity Shell Company | false | |
Entity Bankruptcy Proceedings, Reporting Current | true | |
Entity Common Stock, Shares Outstanding | 43,030,885 | |
Common Stock [Member] | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Common stock, 0.0001 par value per share | |
Trading Symbol | SABS | |
Security Exchange Name | NASDAQ | |
Warrants Each Exercisable for Common Stock [Member] | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share | |
Trading Symbol | SABSW | |
Security Exchange Name | NASDAQ |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Current assets | ||
Cash and cash equivalents | $ 8,332,188 | $ 33,206,712 |
Restricted cash | 0 | 6,338,306 |
Accounts receivable, net | 12,942,037 | 8,010,708 |
Prepaid expenses | 907,865 | 864,513 |
Total current assets | 22,182,090 | 48,420,239 |
Long-term prepaid insurance | 501,388 | |
Operating lease right-of-use assets | 1,870,518 | 2,615,204 |
Financing lease right-of-use assets | 3,921,589 | 4,019,322 |
Property, plant and equipment, net | 24,031,908 | 24,314,455 |
Total assets | 52,507,493 | 79,369,220 |
Current liabilities | ||
Accounts payable | 5,484,276 | 4,458,525 |
Forward share purchase liability | 6,338,306 | |
Notes payable | 25,013 | 25,013 |
Operating lease liabilities, current portion | 1,212,862 | 1,142,413 |
Finance lease liabilities, current portion | 140,891 | 161,050 |
Due to related party | 2,367 | |
Deferred grant income | 100,000 | |
Accrued expenses and other current liabilities | 10,238,212 | 12,455,888 |
Total current liabilities | 17,101,254 | 24,683,562 |
Operating lease liabilities, noncurrent | 762,775 | 1,653,185 |
Finance lease liabilities, noncurrent | 3,662,541 | 3,762,430 |
Warrant liabilities | 357,516 | 10,720,130 |
Total liabilities | 21,884,086 | 40,819,307 |
Commitments and contingencies (Note 17) | ||
Stockholders equity | ||
Preferred stock; $0.0001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively | ||
Common stock; $0.0001 par value; 490,000,000 shares authorized at September 30, 2022 and December 31, 2021; 43,577,543 and 43,487,279 shares issued, respectively, and 43,030,885 and 43,487,279 outstanding at September 30, 2022 and December 31, 2021, respectively | 4,358 | 4,349 |
Treasury stock, at cost; 546,658 and 0 shares held at September 30, 2022 and December 31, 2021, respectively | (5,521,246) | |
Additional paid-in capital | 76,135,447 | 67,674,515 |
Accumulated deficit | (39,995,152) | (29,128,951) |
Total stockholders' equity | 30,623,407 | 38,549,913 |
Total liabilities and stockholders equity | $ 52,507,493 | $ 79,369,220 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Sep. 30, 2022 | Dec. 31, 2021 |
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 490,000,000 | 490,000,000 |
Common stock, shares issued | 43,577,543 | 43,487,279 |
Common stock, shares outstanding | 43,030,885 | 43,487,279 |
Treasury stock, shares | 546,658 | 0 |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue | ||||
Total revenue | $ 3,589,708 | $ 14,680,589 | $ 21,743,309 | $ 49,817,825 |
Operating expenses | ||||
Research and development | 7,352,978 | 15,070,265 | 29,300,405 | 46,535,671 |
General and administrative | 4,044,046 | 3,600,678 | 13,500,512 | 9,331,125 |
Total operating expenses | 11,397,024 | 18,670,943 | 42,800,917 | 55,866,796 |
Loss from operations | (7,807,316) | (3,990,354) | (21,057,608) | (6,048,971) |
Changes in fair value of warrant liabilities | 782,962 | 10,362,614 | ||
Gain on debt extinguishment of Paycheck Protection Program SBA Loan | 665,596 | |||
Other income | 1,527 | 3,953 | 1,527 | 3,953 |
Interest expense | (70,626) | (78,558) | (213,885) | (228,184) |
Interest income | 17,385 | 3,769 | 41,143 | 14,571 |
Total other income (expense) | 731,248 | (70,836) | 10,191,399 | 455,936 |
Loss before income taxes | (7,076,068) | (4,061,190) | (10,866,209) | (5,593,035) |
Net loss | $ (7,076,068) | $ (4,061,190) | $ (10,866,209) | $ (5,593,035) |
Loss per common share attributable to the Company's shareholders | ||||
Basic loss per common share | $ (0.16) | $ (0.16) | $ (0.25) | $ (0.22) |
Diluted loss per common share | $ (0.16) | $ (0.16) | $ (0.25) | $ (0.22) |
Weighted-average common shares outstanding - basic | 43,030,885 | 25,973,406 | 43,042,379 | 25,973,406 |
Weighted-average common shares outstanding - diluted | 43,030,885 | 25,973,406 | 43,042,379 | 25,973,406 |
Grant Revenue [Member] | ||||
Revenue | ||||
Total revenue | $ 3,589,708 | $ 14,680,589 | $ 21,743,309 | $ 49,817,825 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Stockholders' Equity - USD ($) | Total | Common Stock [Member] | Additional Paid-In Capital [Member] | Treasury Stock [Member] | Accumulated Deficit [Member] |
Beginning balance, value at Dec. 31, 2020 | $ 39,007,835 | $ 2,598 | $ 50,989,657 | $ (11,984,420) | |
Beginning balance, shares at Dec. 31, 2020 | 25,973,406 | ||||
Stock-based compensation | 349,115 | 349,115 | |||
Net income (loss) | 1,409,834 | 1,409,834 | |||
Ending balance, value at Mar. 31, 2021 | 40,766,784 | $ 2,598 | 51,338,772 | (10,574,586) | |
Ending balance, shares at Mar. 31, 2021 | 25,973,406 | ||||
Beginning balance, value at Dec. 31, 2020 | 39,007,835 | $ 2,598 | 50,989,657 | (11,984,420) | |
Beginning balance, shares at Dec. 31, 2020 | 25,973,406 | ||||
Net income (loss) | (5,593,035) | ||||
Ending balance, value at Sep. 30, 2021 | 35,078,010 | $ 2,598 | 52,652,867 | (17,577,455) | |
Ending balance, shares at Sep. 30, 2021 | 25,973,406 | ||||
Beginning balance, value at Mar. 31, 2021 | 40,766,784 | $ 2,598 | 51,338,772 | (10,574,586) | |
Beginning balance, shares at Mar. 31, 2021 | 25,973,406 | ||||
Stock-based compensation | 433,431 | 433,431 | |||
Net income (loss) | (2,941,679) | (2,941,679) | |||
Ending balance, value at Jun. 30, 2021 | 38,258,536 | $ 2,598 | 51,772,203 | (13,516,265) | |
Ending balance, shares at Jun. 30, 2021 | 25,973,406 | ||||
Stock-based compensation | 880,664 | 880,664 | |||
Net income (loss) | (4,061,190) | (4,061,190) | |||
Ending balance, value at Sep. 30, 2021 | 35,078,010 | $ 2,598 | 52,652,867 | (17,577,455) | |
Ending balance, shares at Sep. 30, 2021 | 25,973,406 | ||||
Beginning balance, value at Dec. 31, 2021 | 38,549,913 | $ 4,349 | 67,674,515 | (29,128,951) | |
Beginning balance, shares at Dec. 31, 2021 | 43,487,279 | ||||
Issuance of common for exercise of stock options | 7,830 | $ 1 | 7,829 | ||
Issuance of common stock for exercise of stock options, shares | 14,500 | ||||
Forward Share Purchase Agreement, final settlement | 817,060 | 817,060 | |||
Repurchase of common stock pursuant to the Forward Share Purchase Agreement, value | 5,521,246 | $ (5,521,246) | |||
Repurchase of common stock pursuant to the Forward Share Purchase Agreement, shares | (546,658) | ||||
Stock-based compensation | 897,600 | 897,600 | |||
Net income (loss) | 985,863 | 985,863 | |||
Ending balance, value at Mar. 31, 2022 | 41,258,266 | $ 4,350 | 74,918,250 | $ (5,521,246) | (28,143,088) |
Ending balance, shares at Mar. 31, 2022 | 43,501,779 | (546,658) | |||
Beginning balance, value at Dec. 31, 2021 | 38,549,913 | $ 4,349 | 67,674,515 | (29,128,951) | |
Beginning balance, shares at Dec. 31, 2021 | 43,487,279 | ||||
Net income (loss) | (10,866,209) | ||||
Ending balance, value at Sep. 30, 2022 | 30,623,407 | $ 4,358 | 76,135,447 | $ (5,521,246) | (39,995,152) |
Ending balance, shares at Sep. 30, 2022 | 43,577,543 | (546,658) | |||
Beginning balance, value at Mar. 31, 2022 | 41,258,266 | $ 4,350 | 74,918,250 | $ (5,521,246) | (28,143,088) |
Beginning balance, shares at Mar. 31, 2022 | 43,501,779 | (546,658) | |||
Issuance of common for exercise of stock options | 69,141 | $ 8 | 69,133 | ||
Issuance of common stock for exercise of stock options, shares | 75,764 | ||||
Stock-based compensation | 569,861 | 569,861 | |||
Net income (loss) | (4,775,996) | (4,775,996) | |||
Ending balance, value at Jun. 30, 2022 | 37,121,272 | $ 4,358 | 75,557,244 | $ (5,521,246) | (32,919,084) |
Ending balance, shares at Jun. 30, 2022 | 43,577,543 | (546,658) | |||
Stock-based compensation | 578,203 | 578,203 | |||
Net income (loss) | (7,076,068) | (7,076,068) | |||
Ending balance, value at Sep. 30, 2022 | $ 30,623,407 | $ 4,358 | $ 76,135,447 | $ (5,521,246) | $ (39,995,152) |
Ending balance, shares at Sep. 30, 2022 | 43,577,543 | (546,658) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Cash flows from operating activities: | ||
Net income (loss) | $ (10,866,209) | $ (5,593,035) |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||
Gain on debt extinguishment of Paycheck Protection Program SBA Loan | (665,596) | |
Depreciation and amortization | 2,270,621 | 868,630 |
Amortization of right-of-use assets | 97,733 | 123,777 |
Stock-based compensation expense | 2,045,664 | 1,663,210 |
Gain on sale of equipment | (15,793) | (5,488) |
Change in fair value of warrant liabilities | (10,362,614) | |
Changes in operating assets and liabilities | ||
Accounts receivable | (4,931,330) | 10,356,280 |
Prepaid expenses | (544,737) | 331,559 |
Operating lease right-of-use assets | (75,276) | (45,964) |
Accounts payable | 1,025,751 | (3,273,848) |
Due to related party | (2,367) | (2,727) |
Deferred grant income | (100,000) | |
Accrued expense and other current liabilities | (2,217,676) | 3,108,244 |
Net cash (used in) provided by operating activities | (23,676,233) | 6,865,042 |
Cash flows from investing activities: | ||
Proceeds from the sale of equipment | 76,390 | |
Purchases of equipment | (2,048,660) | (8,581,735) |
Net cash used in investing activities | (1,972,270) | (8,581,735) |
Cash flows from financing activities: | ||
Payments related to the Forward Share Purchase Agreement | (5,521,246) | |
Principal payments on finance leases | (120,053) | (142,928) |
Proceeds from exercise of stock options | 76,972 | |
Net cash used in financing activities | (5,564,327) | (142,928) |
Net decrease in cash, cash equivalents, and restricted cash | (31,212,830) | (1,859,621) |
Cash, cash equivalents, and restricted cash | ||
Beginning of year | 39,545,018 | 12,610,383 |
End of period | 8,332,188 | 10,750,762 |
Supplemental disclosures: | ||
Cash paid for interest | 143,259 | 228,184 |
Supplemental information on non-cash investing and finance activities: | ||
Right-of-use assets obtained in exchange for operating lease liabilities | $ 65,088 | $ 260,682 |
Nature of Business
Nature of Business | 9 Months Ended |
Sep. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of Business | (1) Nature of Business On October 22, 2021 (the "Closing Date"), we consummated the business combination contemplated by the agreement and plan of merger, dated as of June 21, 2021, as amended on August 12, 2021, made by and among Big Cypress Acquisition Corp., a Delaware corporation (“BCYP”), Big Cypress Merger Sub Inc., a Delaware corporation (“Merger Sub”), SAB Biotherapeutics, Inc., a Delaware corporation (“SAB” or the “Company”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative, agent and attorney-in-fact of the SAB Stockholders. Upon closing of the Business combination, Big Cypress Merger Sub merged with SAB Biotherapeutics, with SAB Biotherapeutics as the surviving company of the merger. Upon closing of the business combination, Big Cypress Acquisition Corp. changed its name to “SAB Biotherapeutics, Inc.”. SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. SAB’s novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine ) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. However, SAB's platform is the first to produce fully human antibodies in large animals. The COVID-19 pandemic continues to evolve, and the extent to which it may impact the Company’s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions, and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease. The Company is following, and will continue to follow, recommendations from the U.S. Centers for Disease Control and Prevention, as well as federal, state, and local governments. To date, the Company has not experienced material business disruptions, but it cannot be certain of the future impact of the COVID-19 pandemic on its business and consolidated financial statements. Going Concern As of September 30, 2022, the Company has experienced net losses, negative cash flows from operations and had an accumulated deficit of $ 40 million. The Company anticipates to continue to generate losses for the foreseeable future, and expects the losses to increase as the Company continues the development of, and seek regulatory approvals for, product candidates, and begin commercialization of products. As a result, the Company will require additional capital to fund operations in order to support long-term plans, in particular, following the JPEO Rapid Response Contract Termination. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued. To continue as a going concern, the Company will need, among other things, to raise additional capital resources. The Company plans to seek additional funding through a combination of equity or debt financings, or other third-party financing, collaborative or other funding arrangements. Should the Company seek additional financing from outside sources, the Company may not be able to raise such financing on terms acceptable to the Company or at all. If the Company is unable to raise additional capital when required or on acceptable terms, the Company may be required to scale back or discontinue the advancement of product candidates, reduce headcount, liquidate our assets, file for bankruptcy, reorganize, merge with another entity, or cease operations. The unaudited consolidated financial statements as of September 30, 2022, have been prepared on the basis that the Company will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability for the Company to continue as a going concern. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | (2) Summary of Significant Accounting Policies A summary of the significant accounting policies applied in preparation of the accompanying consolidated financial statements is set forth below. Basis of presentation The financial statements have been prepared in conformity with U.S. Generally Accepted Accounting Principles ("GAAP") and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, BCYP is treated as the “acquired” company and SAB Biotherapeutics is treated as the acquirer for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of SAB Biotherapeutics issuing stock for the net assets of BCYP, accompanied by a recapitalization. The net assets of BCYP are stated at historical cost, with no goodwill or other intangible assets recorded. SAB Biotherapeutics was determined to be the accounting acquirer based on the following predominant factors: • SAB Biotherapeutics’ shareholders have the largest portion of voting rights in the Company; • the Board and Management are primarily composed of individuals associated with SAB Biotherapeutics; • the operations of SAB comprise the ongoing operations of the Company. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of SAB Biotherapeutics. At the Closing Date, and subject to the terms and conditions of the Merger Agreement, each share of SAB Biotherapeutics common stock, par value $ 0.0001 per share, and each share of the SAB Biotherapeutics convertible preferred stock that was convertible into a share of SAB Biotherapeutics common stock at a one -to-one ratio, was converted into Common Stock equal to approximately 0.4653 (the "Exchange Ratio"). The shares and corresponding capital amounts and losses per share, prior to the Business Combination, have been retroactively restated based on shares reflecting the Exchange Ratio established in the Business Combination. Emerging growth company status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Principles of consolidation The accompanying consolidated financial statements include the results of the Company and its wholly owned subsidiaries, SAB Capra, LLC and Aurochs, LLC. Intercompany balances and transactions have been eliminated in consolidation. Significant risks and uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, the results of research and development efforts, clinical trial activities of the Company’s product candidates, the Company’s ability to obtain regulatory approval to market its product candidates, competition from products manufactured and sold or being developed by other companies, and the Company’s ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and obtaining and protecting intellectual property. Funding from government grants is not guaranteed to cover all costs, and additional funding may be needed to cover operational costs as the Company moves forward with our efforts to develop a commercially approved product. The company believes its existing cash reserves and anticipated cash receipts will not be sufficient to fund operations for the twelve months following the date these financials are made available for issuance. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements. The Company has used significant estimates in its determination of stock-based compensation assumptions, determination of the fair value of the Company’s common stock, determination of the fair value of the Private Placement Warrant liabilities, determination of the incremental borrowing rate (“IBR”) used in the calculation of the Company’s right of use assets and lease liabilities, and the valuation allowance on deferred tax assets. Actual amounts realized may differ from these estimates. Cash, cash equivalents, and restricted cash Cash equivalents include short-term, highly liquid instruments, consisting of money market accounts and short-term investments with original maturities at the date of purchase of 90 days or less. Amounts held in escrow by the Company pursuant to the Forward Share Purchase Agreement were reported as restricted cash on the consolidated balance sheet as of December 31, 2021. There were no amounts held in escrow by the Company pursuant to the Forward Share Purchase Agreement as of September 30, 2022. The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the consolidated statements of cash flows is as follows: September 30, September 30, Cash and cash equivalents $ 8,332,188 $ 10,750,762 Restricted cash — — Total cash, cash equivalents, and restricted cash $ 8,332,188 $ 10,750,762 Accounts receivable Accounts receivable are carried at original invoice amount, less an allowance for doubtful accounts. The Company estimates an allowance for doubtful accounts for potential credit losses that are expected to be incurred, based on management’s assessment of the collectability of specific accounts, the aging of the accounts receivable, historical information and other currently available evidence. Receivables are written off when deemed uncollectible. To date, no receivables have been written off. The Company had no allowance for doubtful accounts as of September 30, 2022 and December 31, 2021 . Concentration of credit risk The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to credit risk is reduced by placing such deposits in high credit quality federally insured financial institutions. The Company received 100 % of its total revenue through grants from government organizations during the three and nine months ended September 30, 2022 and 2021 . Lease liabilities and right-of-use assets The Company is party to certain contractual arrangements for equipment, lab space, and an animal facility, which meet the definition of leases under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 842, Leases (“ASC 842”). In accordance with ASC 842, the Company recorded right-of-use assets and related lease liabilities for the present value of the lease payments over the lease terms. The Company’s IBR was used in the calculation of its right-of-use assets and lease liabilities. The Company elected not to apply the recognition requirements of ASC 842 to short-term leases, which are deemed to be leases with a lease term of twelve months or less. Instead, the Company recognized lease payments in the Consolidated Statements of Operations on a straight-line basis over the lease term and variable payments in the period in which the obligation for these payments was incurred. The Company elected this policy for all classes of underlying assets. Research and development expenses Expenses incurred in connection with research and development activities are expensed as incurred. These include licensing fees to use certain technology in the Company’s research and development projects, fees paid to consultants and various entities that perform certain research and testing on behalf of the Company, and expenses related to salaries, benefits, and stock-based compensation granted to employees in research and development functions. During the three and nine months ended September 30, 2022 and 2021, the Company had contracts with multiple contract research organizations (“CRO”) to complete studies as part of research grant agreements. In the case of SAB-185, the CRO has been contracted and paid by the US government—as of September 30, 2022 there is no active CRO engaged by the Company in work on SAB-185. For SAB-176, PPD Development, LP acting as the CRO oversaw the Phase 1 safety study. The terms of that agreement are subject to confidentiality, and the status of the agreement is that it is current, in good standing and approxi mately 90 % of the contract has been paid as of September 30, 2022. SAB has also contracted with hVIVO Services Limited to conduct the Phase 2a influenza study on SAB-176. The terms of that agreement are subject to confidentiality, and the status of the agreement is that it is current, in good standing and approximate ly 90 % of the co ntract has been paid as of September 30, 2022 . Equipment The Company records equipment at cost less depreciation. Depreciation is calculated using straight-line methods over the following estimated useful lives: Animal facility equipment 7 years Laboratory equipment 7 years Leasehold improvements Shorter of asset life or lease term Office furniture & equipment 5 years Vehicles 5 years Repairs and maintenance expenses are expensed as incurred. Impairment of long-lived assets The Company reviews the recoverability of long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. If necessary, the Company compares the estimated undiscounted future net cash flows to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known. The Company believes that long-lived assets are recoverable, and no impairment was deemed necessary, during the three and nine months ended September 30, 2022 and 2021 . Stock-based compensation FASB ASC Topic 718, Compensation – Stock Compensation , prescribes accounting and reporting standards for all share-based payment transactions in which employee and non-employee services are acquired. The Company recognizes compensation cost relating to stock-based payment transactions using a fair-value measurement method, which requires all stock-based payments to employees, directors, and non-employee consultants, including grants of stock options, to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. Prior to the Business Combination, the grant date fair value of the Company's common stock was typically determined by the Company's board of directors with the assistance of management and a third-party valuation specialist. Subsequent to the Business Combination, the board of directors elected to determine the fair value of our post-merger common stock based on the closing market price at closing on the date of grant. In determining the fair value of stock-based awards, the Company utilizes the Black-Scholes option-pricing model, which uses both historical and current market data to estimate fair value. The Black-Scholes option-pricing model incorporates various assumptions, such as the value of the underlying common stock, the risk-free interest rate, expected volatility, expected dividend yield, and expected life of the options. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. No awards may have a term in excess of ten years. Forfeitures are recorded when they occur. Stock-based compensation expense is classified in the consolidated statements of operations based on the function to which the related services are provided. The company recognizes stock-based compensation expense over the expected term. Income taxes Deferred income taxes reflect future tax effects of temporary differences between the tax and financial reporting basis of the Company’s assets and liabilities measured using enacted tax laws and statutory tax rates applicable to the periods when the temporary differences will affect taxable income. When necessary, deferred tax assets are reduced by a valuation allowance, to reflect realizable value, and all deferred tax balances are reported as long-term on the consolidated balance sheet. Accruals are maintained for uncertain tax positions, as necessary. Income tax expense includes the current tax liability from operations and the change in deferred income taxes during the year. Current tax liabilities or receivables are recognized for estimated income tax payable and/or refundable for the current year. The Company uses a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The Company has elected to treat interest and penalties related to income taxes, to the extent they arise, as a component of income taxes. Revenue recognition The Company’s revenue is primarily generated through grants from government and other (non-government) organizations. Grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities , and that the grants are not within the scope of ASC 606, Revenue from Contracts with Customers , as the organizations providing the grants do not meet the definition of a customer. Expenses for grants are tracked by using a project code specific to the grant, and the employees also track hours worked by using the project code. Comprehensive income (loss) The Company had no items of comprehensive income (loss) other than its net income (loss). Litigation From time to time, the Company is involved in legal proceedings, investigations and claims generally incidental to its normal business activities. In accordance with U.S. GAAP, the Company accrues for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal costs in connection with loss contingencies are expensed as incurred. Earnings per share In accordance with ASC 260, Earnings per Share (“ASC 260”), basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding during the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding for the period including potential dilutive common shares such as stock options. Segment reporting In accordance with ASC 280, Segment Reporting , the Company’s business activities are organized into one reportable segment, as only the Company’s operating results in their entirety are regularly reviewed by the Company’s chief operating decision maker to make decisions about resources to be allocated and to assess performance. Common stock valuations Prior to the Business Combination, the Company was required to periodically estimate the fair value of its common stock with the assistance of an independent third-party valuation firm, as discussed above, when issuing stock options and computing estimated stock-based compensation expense. The assumptions underlying these valuations represented the Company's best estimates, which involved inherent uncertainties and the application of significant levels of judgment. In order to determine the fair value of its common stock, the Company considered, among other items, previous transactions involving the sale of our securities, our business, financial condition and results of operations, economic and industry trends, the market performance of comparable publicly traded companies, and the lack of marketability of our common stock. Subsequent to the Business Combination, the Company now determines the fair value of common stock based on the closing market price at closing on the date of grant. Compensation expense related to stock-based transactions is measured and recognized in the financial statements at fair value of the post-merger common stock based on the closing market price at closing on the date of grant. Stock-based compensation expense is measured at the grant date based on the fair value of the equity award and is recognized as expense over the requisite service period, which is generally the vesting period, on the straight-line method. The Company estimates the fair value of each stock option award on the date of grant using the Black-Scholes option-pricing model. Determining the fair value of stock option awards at the grant date requires judgment, including estimating the expected volatility, expected term, risk-free interest rate, and expected dividends. |
New Accounting Standards
New Accounting Standards | 9 Months Ended |
Sep. 30, 2022 | |
New Accounting Standards | |
New Accounting Standards | (3) New accounting standards Recently-adopted standards In May 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options . The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company adopted ASU 2021-04 at January 1, 2022 , and the adoption did no t have a material impact on its consolidated financial statements. In July 2021, the FASB issued ASU 2021-05, Leases (Topic 842) Lessors - Certain Leases with Variable Lease Payments , to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities as well as disclosing key information about leasing transactions. This guidance is effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years for public business entities. The Company adopted ASU 2021-05 at January 1, 2022 , and the adoption did no t have a material impact on its consolidated financial statements. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance . This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. The guidance in ASU 2021-10 is effective for financial statements of all entities, including private companies, for annual periods beginning after December 15, 2021, with early application permitted. Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. The Company adopted ASU 2021-10 at January 1, 2022 , and the adoption did no t have a material impact on its consolidated financial statements. Recently-issued standards In July 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires the measurement of all expected credit losses of financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. In addition, the ASU amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. ASU 2016-13 is effective for periods beginning after December 15, 2022, and interim periods within those fiscal years. The Company is currently evaluating the impact this ASU may have on its consolidated financial statements but does not expect it to have a material impact. In October 2021, the FASB issued ASU 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). This ASU requires that an acquirer entity in a business combination recognize and measure contract assets and liabilities acquired in a business combination at the acquisition date in accordance with Topic 606 as if the acquirer entity had originated the contracts. This ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those years. Early application of the amendments is permitted but should be applied to all acquisitions occurring in the annual period of adoption. The amendment should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating the impact this ASU may have on its consolidated financial statements but does not expect it to have a material impact. In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (Topic 815) (“ASU 2022-01”), which clarifies the guidance on fair value hedge accounting of interest rate risk for portfolios of financial assets. The standard is effective for public entities in fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted on any date on or after the issuance of ASU 2017-12. The Company is currently evaluating the impact this ASU may have on its consolidated financial statements but does not expect it to have a material impact. In March 2022, the FASB issued ASU 2022-02, Financial Instruments - Credit Losses (Topic 326), Troubled Debt Restructurings and Vintage Disclosures (“ASU 2022-02”). ASU 2022-02 eliminates the current guidance on troubled debt restructurings ("TDRs"), enhances current and introduces new disclosure requirements related to loan modifications. ASU 2022-02 is effective for the Company for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact this ASU may have on its consolidated financial statements but does not expect it to have a material impact. In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies the guidance on the fair value measurement of an equity security that is subject to a contractual sale restriction and requires specific disclosures related to such an equity security. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact this ASU may have on its consolidated financial statements but does not expect it to have a material impact. In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations (“ASU 2022-04”). ASU 2022-04 makes a number of changes meant to add certain disclosure requirements for a buyer in a supplier finance program. The amendments require a buyer that uses supplier finance programs to make annual disclosures about the program’s key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period and associated rollforward information. Only the amount outstanding at the end of the period must be disclosed in interim periods. The amendments are effective for all entities for fiscal years beginning after December 15, 2022, on a retrospective basis, including interim periods within those fiscal years, except for the requirement to disclose rollforward information, which is effective prospectively for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently evaluating the impact this ASU may have on its consolidated financial statements but does not expect it to have a material impact. |
Reverse Recapitalization and Bu
Reverse Recapitalization and Business Combination | 9 Months Ended |
Sep. 30, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
Reverse Recapitalization and Business Combination | (4) Reverse Recapitalization and Business Combination On the Closing Date, BCYP closed the Business Combination with SAB Biotherapeutics, as a result of which SAB Biotherapeutics became a wholly owned subsidiary of BCYP. While BCYP was the legal acquirer of SAB Biotherapeutics in the Business Combination, for accounting purposes, the Business Combination is treated as a Reverse Recapitalization. SAB Biotherapeutics is treated as the accounting acquirer with historical financial statements of SAB Biotherapeutics becoming the historic financial statements of BCYP (renamed SAB Biotherapeutics, Inc.) upon consummation of the Business Combination. Under this method of accounting, BCYP is treated as the "acquired" company and SAB Biotherapeutics is treated as the acquirer for financial reporting purposes. For accounting reporting purposes, the Business Combination was treated as the equivalent of SAB Biotherapeutics issuing stock for the net assets of BCYP, accompanied by a recapitalization. The net assets of BCYP were stated at historical cost, with no goodwill or other intangible assets recorded. Pursuant to the Business Combination Agreement, the aggregate consideration payable to stockholders of SAB Biotherapeutics at the Closing Date consisted of 36,465,343 shares of New SAB Biotherapeutics common stock, par value $ 0.0001 per share ("Common Stock"). Each option of SAB Biotherapeutics that was outstanding and unexercised immediately prior to the Effective Time (whether vested or unvested) was assumed by BCYP and converted into an option to acquire an adjusted number of shares of Common Stock at an adjusted exercise price per share, in each case, pursuant to the terms of the Business Combination Agreement (the "Rollover Options"). Additionally, the Business Combination Agreement included an earnout provision whereby the shareholders of SAB Biotherapeutics shall be entitled to receive additional consideration (“Earnout Shares”) if the Company meets certain Volume Weighted Average Price (“VWAP") thresholds, or a change in control with a per share price exceeding the VWAP thresholds within a five-year period immediately following the Closing. The Earnout Shares shall be released in four equal increments as follows: (i) 25 % of the Earnout Shares shall be released if, at any time during the five ( 5 )-year period immediately following the Closing Date, the VWAP of the Company's publicly traded common stock is greater than or equal to $ 15.00 for any twenty ( 20 ) trading days within a period of thirty ( 30 ) consecutive trading days (the “First Earnout”). (ii) 25 % of the Earnout Shares shall be released if, at any time during the five ( 5 )-year period immediately following the Closing Date, the VWAP of the Company's publicly traded common stock is greater than or equal to $ 20.00 for any twenty ( 20 ) trading days within a period of thirty ( 30 ) consecutive trading days (the “Second Earnout”). (iii) 25 % of the Earnout Shares shall be released if, at any time during the five ( 5 )-year period immediately following the Closing Date, the VWAP of the Company's publicly traded common stock is greater than or equal to $ 25.00 for any twenty ( 20 ) trading days within a period of thirty ( 30 ) consecutive trading days (the “Third Earnout”). (iv) 25 % of the Earnout Shares shall be released if, at any time during the five ( 5 )-year period immediately following the Closing Date, the VWAP of the Company's publicly traded common stock is greater than or equal to $ 30.00 for any twenty ( 20 ) trading days within a period of thirty ( 30 ) consecutive trading days (the “Fourth Earnout” and together with the First Earnout, the Second Earnout and the Third Earnout, the “Earnouts”). At the Effective Time, each outstanding share of SAB Biotherapeutics common stock, including shares of SAB Biotherapeutics common stock resulting from the conversion of outstanding shares of SAB Biotherapeutics preferred stock (as calculated pursuant to the SAB Biotherapeutics certificate of incorporation), immediately prior to the Effective Time, was converted into the right to receive a pro rata portion of the total consideration and the contingent right to receive a pro rata portion of the Earnout Shares. Pursuant to the terms of the Business Combination Agreement, SAB Biotherapeutics’ securityholders (including vested option holders) who own SAB Biotherapeutics securities immediately prior to the Closing Date will have the contingent right to receive their pro rata portion of (i) an aggregate of 12,000,000 shares of Common Stock (“Earnout Shares”), of which 1,508,063 are contingently issuable based upon future satisfaction of the aforementioned VWAP thresholds. The remaining 10,491,937 are legally issued and outstanding, if the Company does not meet the above VWAP thresholds, or a change in control with a per share price below the VWAP thresholds occurs within a five-year period immediately following the Closing Date, the shares will be returned to the Company. The Earnout Shares are indexed to our equity and meet the criteria for equity classification. On the Closing Date, the fair value of the 12,000,000 Earnout Shares was $ 101.3 million. We reflected the Earnout Shares in the consolidated balance sheet at December 31, 2021 as a stock dividend by reducing additional paid-in capital, which was offset by the increase in additional paid-in capital associated with the Business Combination. Preceding the Business Combination, on October 12, 2021, BCYP entered into a Forward Share Purchase Agreement (the “Forward Share Purchase Agreement”) with Radcliffe SPAC Master Fund, L.P., a Cayman Islands exempted limited partnership (“Radcliffe”). Under the Forward Share Purchase Agreement, Radcliffe shall sell and transfer to BCYP, and BCYP shall purchase from Radcliffe, up to 1,390,000 shares of common stock owned by Radcliffe at the closing of the Business Combination at a per Share price (the “Purchase Price”) equal to $ 10.10 per share (the "Market Sales Price"). Further, BCYP shall purchase the remaining shares held by Radcliffe not sold in the open market in excess of the Market Sales Price at the later of (a) the 90 th day after the closing of the Business Combination, or (b) the first business day following the 95 th day after the closing of the Business Combination if BCYP directs Radcliffe to sell shares at a mutually agreed upon price other than the Market Sales Price. Pursuant to the treatment of the Business Combination as a reverse recapitalization, SAB Biotherapeutics assumed the liability position as it existed as of the Effective Time. The net assets of the acquired entity were adjusted to include a forward share purchase liability of $ 13,098,599 . In connection with the Business Combination, an amount matching the assumed forward share purchase liability was transferred into escrow, pending final settlement of the Forward Share Purchase Agreement in January 2022. Given the short-term nature of the Forward Share Purchase Agreement, the Company did not present value the forward share purchase liability. Subsequent settlements whereby Radcliffe sold shares in the open market in excess of the Market Sales Price were treated as a reduction in the assumed forward share purchase liability, with an offsetting increase in equity of the Company. Prior to December 31, 2021, a portion of the forward share purchase liability was settled. As of December 31, 2021, the forward share purchase liability balance was $ 6,338,306 on the consolidated balance sheet. The forward share purchase liability was settled in full during the first quarter of 2022. As of December 31, 2021, the Company held $ 6.3 million in escrow pending the final settlement of the Forward Share Purchase Agreement; upon final settlement of the Forward Share Purchase Agreement, $ 817,060 in cash was released to the Company and the remaining $ 5.5 million was delivered to Radcliffe for the repurchase of 546,658 shares of the Company's common stock—these shares are accounted for as treasury stock at cost within the consolidated statements of changes in stockholders’ equity. |
Revenue
Revenue | 9 Months Ended |
Sep. 30, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | (5) Revenue During the three and nine months ended September 30, 2022 and 2021, the Company worked on the following grants: Government grants The total revenue for government grants was approximately $ 3.6 million and $ 14.6 million , respectively, the three months ended September 30, 2022 and 2021, and $ 21.7 million and $ 49.8 million , respectively, for the nine months ended September 30, 2022 and 2021. National Institute of Health – National Institute of Allergy and Infectious Disease (“NIH-NIAID”) (Federal Award #1R44AI117976-01A1) – this grant was for $ 1.4 million and started in September 2019 through August 2021. Grant income recognized was approximately $ 0 and $ 306,000 , respectively, for the three months ended September 30, 2022 and 2021, and $ 30,000 and $ 457,000 , respectively, for the nine months ended September 30, 2022 and 2021. The Company applied for an extension on the grant funding, and the extension is pending approval—the Company has not historically experienced challenges renewing grant funding. If approved, there is approximately $ 184,000 in funding remaining for this grant as of September 30, 2022. NIH-NIAID (Federal Award #1R41AI131823-02) – this grant was for approximately $ 1.5 million and started in April 2019 through March 2021. The grant was subsequently amended to extend the date through March 2022. Grant income recognized was approximately $ 150,000 and $ 13,000 , respectively, for the three months ended September 30, 2022 and 2021, and $ 281,000 and $ 41,000 , respectively, for the nine months ended September 30, 2022 and 2021. There is approximately $ 533,000 in funding remaining for this grant as of September 30, 2022. NIH-NIAID through Geneva Foundation (Federal Award #1R01AI132313-01, Subaward #S-10511-01) – this grant was for approximately $ 2.7 million and started in August 2017 through July 2021. The grant was subsequently amended to extend the date through July 2023. Grant income recognized was approximately $ 39,000 and $ 24,000 , respectively, for the three months ended September 30, 2022 and 2021, and $ 88,000 and $ 72,000 , respectively, for the nine months ended September 30, 2022 and 2021. There is approximately $ 1.4 million in funding remaining for this grant as of September 30, 2022. Department of Defense, Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies (“JPEO”) through Advanced Technology International – this grant was for a potential of $ 25 million, awarded in stages starting in August 2019 and with potential stages running through February 2023. Additional contract modifications were added to this contract in 2020 and 2021 for work on a COVID therapeutic, bringing the contract total to $ 204 million . Grant income recognized was approximately $ 3.4 million and $ 14.3 million , respectively, for the three months ended September 30, 2022 and 2021, and $ 21.3 million and $ 49.2 million , respectively, for the nine months ended September 30, 2022 and 2021. The grants for the JPEO Rapid Response contract are cost reimbursement agreements, with reimbursement of our direct research and development expense (labor and consumables) with an overhead charge (based on actual, reviewed quarterly) and a fixed fee ( 9 %). On August 3, 2022, the Company received notice from the US Department of Defense (“DoD”) to terminate the Department of Defense, Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies (“JPEO”) Rapid Response contract, dated as of August 7, 2019 by and between the Company and the DoD most recently amended as of September 14, 2021, relating to a prototype research and development of a Rapid Response Antibody Program and advanced clinical development through licensure and commercial manufacturing for SAB-185 (the "JPEO Rapid Response Contract Termination"). No termination penalties have been or will be incurred by the Company in connection therewith. The Company anticipates entry into a termination settlement or similar arrangement with the DoD whereby, among other things, the Company expects to be compensated for costs incurred in winding down activity surrounding the JPEO Rapid Response contract. Approximately $ 12.7 million of the Company’s $ 12.9 million in accounts receivable as of September 30, 2022 relates to the JPEO Rapid Response Contract. The Company considered all conditions and barriers associated with the JPEO Rapid Response Contract and associated termination agreement and determined the grant is conditional and revenue will be recognized upon achieving certain milestones and incurring internal costs specifically covered by the grant and termination agreement. Consistent with the Company’s Summary of Significant Accounting Policies in Note 2, under ASC 958-605 revenues will be recognized as the Company incurs related expenses. The Company has determined the barriers to recognition to have been met and collection of these receivables to be probable; however, final approval and payment by the DoD is contingent upon further negotiations, and final execution of the termination settlement documents. |
Earnings per share
Earnings per share | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
Earnings per share | (6) Earnings per share The following is a reconciliation of the numerator and denominator used to calculate basic earnings per share and diluted earnings per share for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Calculation of basic and diluted loss per share Net loss attributable to the Company’s shareholders $ ( 7,076,068 ) $ ( 4,061,190 ) $ ( 10,866,209 ) $ ( 5,593,035 ) Weighted-average common shares outstanding – 43,030,885 25,973,406 43,042,379 25,973,406 Net loss per share, basic and diluted $ ( 0.16 ) $ ( 0.16 ) $ ( 0.25 ) $ ( 0.22 ) The Company’s potentially dilutive securities, which include stock options, restricted stock awards, common stock warrants, earnout shares, and contingently issuable earnout shares have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Stock options and awards 1,004,845 2,570,978 2,181,361 2,077,499 Common stock warrants 5,958,600 — 5,958,600 — Earnout Shares (1) 10,491,937 — 10,491,937 — Contingently issuable Earnout Shares from unexercised 1,508,063 — 1,508,063 — Total 18,963,445 2,570,978 20,139,961 2,077,499 (1) As the Earnout shares are subject to certain vesting requirements not satisfied as of the three and nine months ended September 30, 2022 , the Earnout Shares held in escrow are excluded from calculating both basic and diluted earnings per share. |
Equipment
Equipment | 9 Months Ended |
Sep. 30, 2022 | |
Property, Plant and Equipment [Abstract] | |
Equipment | (7) Equipment As of September 30, 2022 and December 31, 2021, the Company’s equipment was as follows: September 30, December 31, Laboratory equipment $ 8,801,250 $ 7,431,988 Animal facility 8,357,667 8,357,667 Animal facility equipment 1,141,213 1,253,879 Construction-in-progress 404,976 4,608,778 Leasehold improvements 9,280,795 5,700,364 Vehicles 192,683 135,593 Office furniture and equipment 1,233,038 46,202 Total Property, plant and equipment, gross 29,411,622 27,534,471 Less: accumulated depreciation and amortization ( 5,379,714 ) ( 3,220,016 ) Property, plant and equipment, net $ 24,031,908 $ 24,314,455 Depreciation and amortization expense was $ 885,195 and $ 369,366 , respectively, for the three months ended September 30, 2022 and 2021, and $ 2,270,621 and $ 868,630 , respectively, for the nine months ended September 30, 2022 and 2021. All tangible personal property with a useful life of at least three years and a unit acquisition cost of $ 5,000 or more will be capitalized and depreciated over its useful life using the straight-line method of depreciation. The Company will expense the full acquisition cost of tangible personal property below these thresholds in the year of purchase. The basis of accounting for depreciable fixed assets is acquisition cost and any additional expenditures required to make the asset ready for use. The carrying amount at the balance sheet date of long-lived assets under construction-in-progress includes assets purchased, constructed, or being developed internally that are not yet in service. Depreciation commences when the assets are placed in service. The Company has several ongoing construction projects related to the expansion of its operating capacity. As of September 30, 2022 and December 31, 2021, the Company’s construction-in-progress was as follows: September 30, December 31, New office space at Headquarters $ 14,859 $ 11,183 Laboratory space at Headquarters — 2,506,482 Laboratory equipment at Headquarters 171,781 246,801 IT equipment at Headquarters 80,525 212,209 Software 137,811 137,811 Bioreactors — 1,280,728 Other — 213,564 Total construction-in-progress $ 404,976 $ 4,608,778 |
Leases
Leases | 9 Months Ended |
Sep. 30, 2022 | |
Leases [Abstract] | |
Leases | (8) Leases The Company has an operating lease for lab space from Sanford Health (a former related party), under a lease that started in June 2014 and ran through June 2019 , at which time the lease was amended to run through August 2024 . This lease can be terminated with one year advance written notice. The lease is for $ 66,993 per month. The operating lease does not include an option to extend beyond the life of the current term. The lease does not provide an implicit rate, and, therefore, the Company used an IBR of 4.54 % as the discount rate when measuring the operating lease liability. The Company estimated the incremental borrowing rate based upon comparing interest rates available in the market for similar borrowings and the credit quality of the Company. The Company entered into a lease for office, laboratory, and warehouse space in November 2020 , the lease was amended in July 2022 to add additional administrative and lab space. This amended lease has a 3-year term, with options to extend for three additional periods of three years each. The options were not included in the right of use calculation as it is unclear as to whether or not the location will meet the Company’s future requirements. The lease cost is $ 38,872 per month. The Company used an IBR of 4.83 % as the discount rate when measuring the operating lease liability. The Company estimated the incremental borrowing rate based upon comparing interest rates available in the market for similar borrowings and the credit quality of the Company. The Company entered into a lease for barn space for the housing of goats in April 2020 . This lease has a 2-year original term, with automatic renewals for a one-year period after the initial term expires until either party terminates. The options were not included in the right of use calculation, as the goat project is mostly funded by government grants, and those grants do not currently extend beyond the initial lease term. The lease cost is $ 665 per month for the first year, then $ 678 per month for the second year. The Company used an IBR of 4.08 % as the discount rate when measuring the operating lease liability. The Company estimated the incremental borrowing rate based upon comparing interest rates available in the market for similar borrowings and the credit quality of the Company. This lease was automatically renewed as an annual short-term operating lease in April of 2022. The Company has the following finance leases: • In December 2018 , the Company entered into a finance lease with Dakota Ag Properties for a new animal facility which includes the surrounding land. The facility and the land have been accounted for as separate lease components. The lease is based upon payback of $ 4,000,000 in construction costs, with a 20-year term at an interest rate of 8 %. The monthly payment for this lease is $ 33,458 . The Company has the option to purchase the asset at any time during the term of the lease for the balance of the unamortized lease payments. • In December 2018 , the Company entered into an equipment lease for a 12,000 -gallon propane tank that is located on the Company’s animal facility. The lease is for five years , with an annual payment of $ 8,199 . The Company has the option to purchase the asset at any time during the term of the lease for the balance of the unamortized lease payments. • In July 2018 , the Company entered into a lease agreement with a bank, for a Ruby Cell Analyzer. The lease agreement is for a five-year term. The monthly payment for this lease is $ 807 . The Company has the option to purchase the asset at the end of the lease for $ 1 . • In March 2019 , the Company entered into two lease agreements for laboratory equipment. The leases are each for a 3-year term and a combined monthly payment of $ 5,956 . Both leases have a $ 1 purchase option at the end of the lease term. These leases ended in the second quarter of 2022 with the Company exercising its option to purchase the leased assets. The lease agreements do not require material variable lease payments, residual value guarantees or restrictive covenants. The amortizable lives of the operating lease assets are limited by their expected lease terms. The amortizable lives of the finance lease assets are limited by their expected lives, as the Company intends to exercise the purchase options at the end of the leases. The following is the estimated useful lives of the finance lease assets: Animal Facility 40 years Equipment 3 – 7 years Land Indefinite The Company’s weighted-average remaining lease term and weighted-average discount rate for operating and finance leases as of September 30, 2022 are: Operating Finance Weighted-average remaining lease term 1.69 years 16.13 years Weighted-average discount rate 4.78 % 7.72 % The table below reconciles the undiscounted future minimum lease payments under non-cancelable leases with terms of more than one year to the total lease liabilities recognized on the consolidated balance sheet as of September 30, 2022: Operating Finance 2022 - remaining $ 315,726 $ 110,994 2023 1,197,025 406,339 2024 535,944 401,496 2025 — 401,496 2026 — 401,496 Thereafter — 4,784,494 Undiscounted future minimum lease payments 2,048,695 6,506,315 Less: Amount representing interest payments ( 73,058 ) ( 2,702,883 ) Total lease liabilities 1,975,637 3,803,432 Less current portion ( 1,212,862 ) ( 140,891 ) Noncurrent lease liabilities $ 762,775 $ 3,662,541 Operating lease expense was approximately $ 304,000 and $ 268,000 , respectively, for the three months ended September 30, 2022 and 2021, and $ 889,000 and $ 789,000 , respectively, for the nine months ended September 30, 2022 and 2021. Operating lease costs are included within research and development expenses on the consolidated statements of operations. Finance lease costs for the three months ended September 30, 2022 and 2021 included approximately $ 25,000 and $ 41,000 , respectively, in right-of-use asset amortization and approximately $ 71,000 and $ 78,000 , respectively, of interest expense. Finance lease costs for the nine months ended September 30, 2022 and 2021 included approximately $ 98,000 and $ 124,000 , respectively, in right-of-use asset amortization and approximately $ 214,000 and $ 228,000 , respectively, of interest expense. Finance lease costs are included within research and development expenses on the consolidated statements of operations. Cash payments under operating and finance leases were approximately $ 309,000 and $ 103,000 , respectively, for the three months ended September 30, 2022. Cash payments under operating and finance leases were approximately $ 930,000 and $ 334,000 , respectively, for the nine months ended September 30, 2022. Cash payments under operating and finance leases were approximately $ 285,000 and $ 131,000 , respectively, for the three months ended September 30, 2021. Cash payments under operating and finance leases were approximately $ 836,000 and $ 372,000 , respectively, for the nine months ended September 30, 2021. Short-term lease expense recognized in the three and nine months ended September 30, 2022 and 2021 , was not material. |
Accrued Expenses and Other Curr
Accrued Expenses and Other Current Liabilities | 9 Months Ended |
Sep. 30, 2022 | |
Payables and Accruals [Abstract] | |
Accrued Expenses and Other Current Liabilities | (9) Accrued Expenses and Other Current Liabilities As of September 30, 2022 and December 31, 2021, accrued expenses and other current liabilities consisted of the following: September 30, December 31, Accrued vacation $ 563,726 $ 552,629 Accrued payroll 211,563 674,858 Accrued construction-in-progress 14,859 548,988 Accrued supplies 391,906 709,027 Accrued consulting 67,497 179,082 Accrued clinical trial expense 343,766 423,634 Accrued outside laboratory services 675,064 128,752 Accrued bonus & severance 1,793,676 1,804,288 Accrued contract manufacturing — 1,000,824 Accrued legal 720,154 833,646 Accrued financing fees payable 5,123,500 5,100,000 Accrued franchise tax payable 82,501 216,251 Other accrued expenses 250,000 283,909 $ 10,238,212 $ 12,455,888 |
Notes Payable
Notes Payable | 9 Months Ended |
Sep. 30, 2022 | |
Debt Disclosure [Abstract] | |
Notes Payable | (10) Notes Payable In December 2017, the Company entered into a loan agreement for the purchase of a tractor for $ 116,661 at a 3.6 % interest rate. The loan included annual payments of $ 25,913 for the next five years starting in December 2018. The tractor loan balance as of September 30, 2022 and December 31, 2021 was $ 25,013 . The total amount of the remaining loan balance is due in full in the fourth quarter of 2022. On March 27, 2020, President Trump signed into law the “Coronavirus Aid, Relief and Economic Security Act (“CARES Act”). In April 2020, the Company entered into a loan agreement (the “PPP Loan”) with First Premier Bank under the Paycheck Protection Program (the “PPP”), which is part of the CARES Act administered by the United States Small Business Administration (“SBA”). As part of the application for these funds, the Company, in good faith, certified that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. The certification further requires the Company to take into account its current business activity and its ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not significantly detrimental to the business. Under the PPP, the Company received proceeds of approximately $ 661,612 . In accordance with the requirements of the PPP, the Company utilized the proceeds from the PPP Loan primarily for payroll costs. The PPP Loan has a 1.00 % interest rate per annum, matures in April 2022 and is subject to the terms and conditions applicable to loans administered by the SBA under the PPP. Under the terms of PPP, all or certain amounts of the PPP Loan may be forgiven if they are used for qualifying expenses, as described in the CARES Act. The Company recorded the entire amount of the PPP Loan as debt. In February 2021, the Company submitted a forgiveness application related to its PPP Loan. In March 2021, the SBA approved the forgiveness of the PPP Loan, plus accrued interest. We recorded a gain on extinguishment of PPP Loan of $ 665,596 for the forgiveness of the PPP Loan and accrued interest within gain on debt extinguishment of Paycheck Protection Program SBA Loan on the consolidated statement of operations for the nine months ended September 30, 2021 . |
Preferred Stock
Preferred Stock | 9 Months Ended |
Sep. 30, 2022 | |
Equity [Abstract] | |
Preferred Stock | (11) Preferred Stock On the Closing Date, pursuant to the Business Combination (as described in Note 4), 17,750,882 outstanding shares of Preferred Stock were automatically converted into 8,259,505 shares of common stock pursuant to the Exchange Ratio. In addition, upon the closing of the Business Combination, pursuant to the terms of the Second Amended and Restated Certificate of Incorporation, the Company authorized 10,000,000 shares of preferred stock with a par value $ 0.0001 . Prior to the Business Combination, in August 2019, the Company’s Certificate of Incorporation was amended to authorize the Company to issue 50,000,000 shares of preferred stock, of which 6,615,000 shares were designated as Series A preferred stock, 2,525,800 shares were designated as series A-1 preferred stock, 4,039,963 shares were designated as series A-2 preferred stock, 3,333,333 shares were designated as series A-2A preferred stock, and 8,571,429 shares were designated as series B preferred stock. The carrying value of Series A preferred stock was $ 1 per share, Series A-1 $ 1.88 per share, Series A-2 & A-2A $ 3.00 per share, and Series B $ 3.50 per share. The preferred stock was entitled to receive noncumulative dividends in preference to any dividend on the common stock when, as, and if declared by the Company’s board of directors. The holders of the preferred stock also were entitled to participate pro rata in any dividends paid on the common stock on an as-if-converted basis. Each holder of preferred stock was entitled to the number of votes equal to the number of shares of common stock that it could be converted into. As long as there were 8,000,000 shares of preferred stock outstanding, the vote or written consent of the holder of the majority of the outstanding preferred stock (all series voting as a single class) was required to approve any amendment of the certificate of incorporation that changes voting, preferences or privileges or restrictions of the preferred stock. In the event of liquidation or winding up of the Company, the preferred stockholders also were entitled to receive in preference to the holders of the common stock the greater of: a) a per share amount equal to their respective original purchase price plus any declared but unpaid dividends (the “Liquidation Preference”); or b) the amount to be paid on the common stock on an as-if-converted basis. The remaining assets would be distributed to the common stockholders. The holders of preferred stock had the right to convert the preferred stock into common stock, at any time, utilizing the then- effective conversion rate. The effective conversion rate as of December 31, 2020 was 1:1. All preferred shares were automatically converted into common shares utilizing the then effective preferred conversion rate upon: a) the closing of the Company’s sale of its common stock in a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933, as amended covering the sale of the Company’s common stock if gross proceeds are at least $ 20,000,000 and the Company’s shares have been listed on a stock exchange, as defined; or b) the election of the holders of a majority of the outstanding shares of preferred stock. With any change of control of the Company or financing, the preferred stockholders were to approve through majority vote any such change in control or financing event approved by the board of directors or the majority of the common stockholders. The preferred stock contained certain anti-dilution provisions, as defined. In addition to the rights described above, series A-2A preferred stock was redeemable at a price equal to $ 5 per preferred share at the option of the investor at any time during the redemption period, which was scheduled to commence in August 2022 and end in August 2023. As a result of the redemption feature, the Company classified the series A-2A preferred stock as mezzanine equity as of January 1, 2020. However, the redemption feature was terminated during the year ended December 31, 2020, and the series A-2A preferred stock was reclassified from mezzanine equity to permanent equity. |
Stock Option Plans
Stock Option Plans | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Stock Option Plans | (12) Stock Option Plans On August 5, 2014, the Company approved a stock option grant plan (the “2014 Equity Incentive Plan”) for employees, directors, and non-employee consultants, which provides for the issuance of options to purchase common stock. The total shares authorized under the plan was originally 8,000,000 ; however, during 2019, the Plan was amended to increase the total shares authorized under the plan to 16,000,000 . As a result of the Business Combination, the 2014 Equity Incentive Plan was amended to reduce the shares authorized to 7,444,800 based upon the impact of the Exchange Ratio. As a result of the Business Combination, the Company adopted the 2021 Omnibus Equity Incentive Plan (hereinafter collectively with the 2014 Equity Incentive Plan referred to as the "Equity Compensation Plans"), representing 11,000,000 shares of common stock reserved for issuance under the 2021 Omnibus Equity Incentive Plan . As of the beginning of the 2022 calendar year, the shares reserved for future issuance increased by, 869,746 , or two percent ( 2 %) of the total number of shares of Common Stock issued and outstanding, to a total of 11,869,746 shares of common stock reserved for issuance under the 2021 Omnibus Equity Incentive Plan. The expected term of the stock options was estimated using the “simplified” method, as defined by the SEC’s Staff Accounting Bulletin No. 107, Share-Based Payment . The volatility assumption was determined by examining the historical volatilities for industry peer companies, as the Company does not have sufficient trading history for its common stock. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the options. The dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has never paid dividends on its common stock and does not anticipate paying dividends on its common stock in the foreseeable future. Therefore, the Company has assumed no dividend yield for purposes of estimating the fair value of the options. Stock Options Stock option activity for employees and non-employees under the Equity Compensation Plans for the nine months ended September 30, 2022 was as follows: Options Weighted Weighted Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding options, December 31, 2021 5,107,672 $ 2.44 5.78 $ 28,948,535 Granted 2,934,051 $ 1.54 Forfeited ( 503,274 ) $ 4.51 Exercised ( 90,264 ) $ 0.85 Expired ( 990 ) $ 4.97 Outstanding options, September 30, 2022 7,447,195 $ 1.97 6.27 $ 353,850 Options vested and exercisable, September 30, 2022 4,057,684 $ 1.47 3.47 $ 353,850 Total unrecognized compensation cost related to non-vested stock options as of September 30, 2022 was approximately $ 5.1 million and is expected to be recognized within future operating results over a weighted-average period of 3.35 years. The weighted average grant date fair value of options granted during the three months ended September 30, 2022 was $ 0.57 per share; no options were granted during the three months ended September 30, 2021. During the three months ended September 30, 2022 and 2021, 108,611 shares with a fair value totaling $ 478 thousand , and 120,626 shares with a fair value totaling $ 395 thousand , respectively, vested. The weighted average grant date fair value of options granted during the nine months ended September 30, 2022 and 2021, was $ 0.78 per share and $ 5.21 per share, respectively. During the nine months ended September 30, 2022 and 2021, 314,380 shares with a fair value totaling $ 1.3 million , and 351,974 shares with a fair value totaling $ 1.3 million , respectively, vested. The estimated fair value of stock options granted to employees and consultants during the three and nine months ended September 30, 2022 and 2021, were calculated using the Black-Scholes option-pricing model using the following assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Expected volatility 97.4 % * 78.0 - 97.4 % 75.9 - 104.3 % Weighted-average volatility 97.4 % * 94.1 % 98.1 % Expected dividends — % * — % — % Expected term (in years) 5.77 - 6.08 * 5.50 - 6.08 6.25 Risk-free rate 3.55 - 3.56 % * 1.38 - 3.56 % 0.14 - 0.59 % * No options were granted during the three months ended September 30, 2021 . Restricted Stock Stock award activity for employees and non-employees under the Equity Compensation Plans for the nine months ended September 30, 2022 was as follows: Number of shares Weighted Unvested as of December 31, 2021 — $ — Granted 350,000 $ 1.72 Vested — $ — Forfeited — $ — Unvested as of September 30, 2022 350,000 $ 1.72 Total unrecognized compensation cost related to non-vested stock awards as of September 30, 2022 was approximately $ 0.6 million and is expected to be recognized within future operating results over a weighted-average period of 3.71 years. Stock-based compensation expense Stock-based compensation expense for the three and nine months ended September 30, 2022 and 2021 was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Research and development $ 165,607 $ 211,841 $ 683,646 $ 726,245 General and administrative 412,596 668,823 1,362,018 936,965 Total $ 578,203 $ 880,664 $ 2,045,664 $ 1,663,210 |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | (13) Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques that would be used to measure fair value into one of three levels: Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. The following tables present information about the Company's assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: As of September 30, 2022 Total Quoted Significant Significant Liabilities: Public Warrant liability $ 345,000 $ 345,000 $ — $ — Private Placement Warrant liability 12,516 — — 12,516 Total $ 357,516 $ 345,000 $ — $ 12,516 As of December 31, 2021 Total Quoted Significant Significant Liabilities: Public Warrant liability $ 10,292,500 $ 10,292,500 $ — $ — Private Placement Warrant liability 427,630 — — 427,630 Total $ 10,720,130 $ 10,292,500 $ — $ 427,630 Public Warrants Each whole Public Warrant entitles the holder to purchase one share of the Company's common stock at a price of $ 11.50 per share , subject to adjustment as discussed herein. The Public Warrants became exercisable 30 days after the Closing Date of the Business Combination and will expire five years after the Closing Date of the Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. Once the warrants become exercisable, the Company may call the warrants for redemption: • in whole and not in part; • at a price of $ 0.01 per warrant; • upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and • if, and only if, the reported last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before the Company send the notice of redemption to the warrant holders. If the Company calls the warrants for redemption as described above, the management will have the option to require any holder that wishes to exercise its warrant to do so on a “cashless basis.” If the management takes advantage of this option, all holders of warrants would pay the exercise price by surrendering their warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the excess of the “fair market value” (defined below) over the exercise price of the warrants by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. As of September 30, 2022 , an aggregate of 5,750,000 Public Warrants were outstanding. Private Placement Warrants The Private Placement Warrants and the common stock issuable upon the exercise of the Private Placement Warrants were not transferable, assignable or saleable until after the completion of the Company's Business Combination. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. As of September 30, 2022 , an aggregate of 208,600 Private Placement Warrants were outstanding. Presentation and Valuation of the Warrants The Warrants (both the Public Warrants and Private Placement Warrants) are accounted for as liabilities in accordance with ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity and were presented within warrant liabilities on the consolidated balance sheet as of September 30, 2022 and December 31, 2021. The initial fair value of the warrant liabilities was measured at fair value at the Closing Date, and changes in the fair value of the warrant liabilities were presented within changes in fair value of warrant liabilities in the consolidated statements of operations for the three and nine months ended September 30, 2022. On the Closing Date, the Company established the fair value of the Private Placement Warrants utilizing both the Black-Scholes Merton formula and a Monte Carlo Simulation (“MCS”) analysis. Specifically, the Company considered an MCS to derive the implied volatility in the publicly listed price of the Public Warrants. The Company then considered this implied volatility in selecting the volatility for the application of a Black-Scholes Merton model for the Private Placement Warrants. The Company determined the fair value of the Public Warrants by reference to the quoted market price. The Public Warrants were classified as a Level 1 fair value measurement, due to the use of the quoted market price, and the Private Placement Warrants held privately by Big Cypress Holdings LLC, a Delaware limited liability company which acted as the Company’s sponsor in connection with the IPO (the "Sponsor"), were classified as a Level 3 fair value measurement, due to the use of unobservable inputs. The following table provides a summary of the changes in our Level 3 fair value measurements: September 30, Balance, December 31, 2021 $ 427,630 Change in fair value of Private Placement Warrant liability ( 317,072 ) Balance, March 31, 2022 $ 110,558 Change in fair value of Private Placement Warrant liability ( 62,580 ) Balance, June 30, 2022 $ 47,978 Change in fair value of Private Placement Warrant liability $ ( 35,462 ) Balance, September 30, 2022 $ 12,516 The initial measurement on the Closing Date for the Public Warrant liability was approximately $ 6.3 million and the fair value of the Public Warrant liability increased by approximately $ 4.0 million during the year ended December 31, 2021 . The fair value of the Public Warrant liability decreased by approximately $ 0.8 million and $ 9.9 million, respectively, for the three and nine months ended September 30, 2022. The key inputs into the valuations as of September 30, 2022 and December 31, 2021 were as follows: September 30, December 31, Risk-free interest rate 4.15 % 1.24 % Expected term remaining (years) 4.06 4.81 Implied volatility 76.5 % 43.0 % Closing common stock price on the measurement date $ 0.70 $ 7.81 As of September 30, 2022 and December 31, 2021 , the Company did no t have any other assets or liabilities that are recorded at fair value on a recurring basis. The Company believes that the carrying amounts of its cash and cash equivalents, accounts receivable, and notes payable approximate their fair values due to their near-term maturities. |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | (14) Income Taxes The effective income tax rate for the nine months ended September 30, 2022 is 0 %, compared with an effective tax rate of 0 % for the year ended December 31, 2021. The calculation of the annual effective tax rate did not produce a reliable estimate, so the actual effective tax rate for the year-to-date period is used as the best estimate of the annual effective tax rate. Starting in 2022, Tax Cuts and Jobs Act amendments to Internal Revenue Code Section 174 will no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. The 2022 first quarter effective income tax rate was impacted by the Section 174 capitalization requirement combined with the restriction on net operating losses to only reduce taxable income by 80 %. The Company continues to record a valuation allowance on its net deferred tax assets. The valuation allowance increased by approximately $ 4.5 million during the nine months ended September 30, 2022 . The Company has not recognized any reserves for uncertain tax positions. |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Sep. 30, 2022 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | (15) Related Party Transactions For the three and nine months ended September 30, 2022 , under the Related Party Transaction Policy the Company adopted in the fourth quarter of 2021, there were no related party transactions with beneficial owners of 5 % or more of any class of the Company’s voting securities, immediate family members of any of the foregoing persons, and any entities in which any of the foregoing is an executive officer or is an owner of 5 % or more ownership interest. For the three and nine months ended September 30, 2021, preceding the Company's Merger and adoption of the aforementioned Related Party Transaction Policy, the Company had related party transactions as follows: • The Company paid consulting fees to a board member, Christine Hamilton, who is also a shareholder, of $ 0 and $ 25,000 , respectively, during the three and nine months ended September 30, 2021. • The Company made lease and insurance payments to Dakota Ag Properties of approximately $ 67,000 and $ 301,000 , respectively, during the three and nine months ended September 30, 2021. Dakota Ag Investments (part of Dakota Ag Properties) is a shareholder of the Company. • The Company made lab supply payments to Sanford Health (which is a shareholder of the Company) totaling approximately $ 15,000 and $ 93,000 , respectively, during the three and nine months ended September 30, 2021 . |
Employee Benefit Plan
Employee Benefit Plan | 9 Months Ended |
Sep. 30, 2022 | |
Retirement Benefits [Abstract] | |
Employee Benefit Plan | (16) Employee Benefit Plan The Company sponsors a defined contribution retirement plan. All the Company’s employees are eligible to be enrolled in the employer-sponsored contributory retirement savings plan, which include features under Section 401(k) of the Internal Revenue Code of 1986, as amended, and provides for Company matching contributions. The Company’s contributions to the plan are determined by its Board of Directors, subject to certain minimum requirements specified in the plan. The Company has historically made matching contributions of 100 % on 3 % of the employee contributions, with an additional 50 % match on the next 2 % of employee contributions. The Company made contributions of approximately $ 91,000 and $ 67,000 , respectively, during the three months ended September 30, 2022 and 2021 and approximately $ 350,000 and $ 245,000 , respectively, during the nine months ended September 30, 2022 and 2021 . |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | (17) Commitments and Contingencies The Company is not a party to any litigation, and, to its best knowledge, no action, suit, or proceeding has been threatened against the Company which are expected to have a material adverse effect on its financial condition, results of operations or liquidity. |
Joint Development Agreement
Joint Development Agreement | 9 Months Ended |
Sep. 30, 2022 | |
Joint Development Agreement | |
Joint Development Agreement | (18) Joint Development Agreement In June 2019, the Company entered into a joint development agreement with the University of South Dakota Research Park, Inc. (“USDRP”) for the construction of a multi-tenant office building and a manufacturing building. Pursuant to the agreement, the Company also entered into a lease agreement for 41,195 square feet of leasable area located in the building. The lease will commence upon completion of the building for an initial term of 12 years at a monthly payment of approximately $ 118,000 . Aurochs, LLC, a wholly owned subsidiary, was founded to manage the construction funds for this project. All pre-construction costs up to a budgeted $ 2.7 million were paid directly by the Company and reimbursed by USDRP. As of September 30, 2022 or December 31, 2021 , USDRP has spent approximately $ 2.12 million in design costs for this facility, with approximately $ 580,000 of the $ 2.7 million budget remaining. There were no receivables or payables for this project as of September 30, 2022 or December 31, 2021 . USDRP and the Company intend to secure outside funding for all expenses incurred after the pre-construction phase. If funding cannot be secured to finance the construction of this facility, the Company will not be required to refund any of the design costs incurred to date. This project is on hold as the Company works to develop existing production capabilities at its current facilities sufficient to support its ongoing research and development plans. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Sep. 30, 2022 | |
Subsequent Events [Abstract] | |
Subsequent Events | (19) Subsequent Events Manufacturing Option Agreement with Emergent BioSolutions Canada, Inc On October 26, 2022, the Company entered into a Manufacturing Option Agreement (the “Manufacturing Agreement”) and Right of First Refusal Agreement (the “RoFR Agreement,” and together with the Manufacturing Agreement, the “Emergent Agreements”) with Emergent BioSolutions Canada, Inc., a wholly-owned subsidiary of Emergent BioSolutions Inc. (“Emergent”). The Emergent Agreements contemplate that the Company and Emergent will enter into one or more binding Master Manufacturing Services Agreements, whereby Emergent will provide contract development and manufacturing services to produce the Company’s fully-human polyclonal antibody products (a “MSA”). Under the terms of an MSA, Emergent will provide end-to-end Good Manufacturing Practice manufacturing services to the Company, including process development and manufacturing clinical investigational drug product to support the Company’s clinical programs, and commercial manufacturing services upon regulatory approval of the Company’s therapeutics. Any MSA will also provide the opportunity for Emergent to utilize the Company’s novel DiversitAb platform for future development of undisclosed programs. Emergent may terminate the Emergent Agreements at its discretion until a definitive MSA is entered into between the parties. Under the Manufacturing Agreement, the Company grants Emergent an exclusive option for the exclusive commercial manufacture of commercial stage product utilizing the Company’s humanized polyclonal antibodies, developed by the Company. The Company will notify Emergent at least 24 months in advance of its first commercial manufacturing needs for such product and at least 12 months in advance for each additional product (subject to certain customary exceptions). Emergent may then exercise the exclusive manufacturing option with respect to such product identified by the Company, and when Emergent determines it has the ability and capacity to manufacture such product, Emergent shall notify the Company within 60 days of its intent to exercise the option for such product. The parties will execute a definitive MSA, in substantially the form attached as Exhibit A to the Manufacturing Agreement, for each such customer product. Under the RoFR Agreement, the Company grants Emergent an exclusive right of first refusal to license and develop the Company’s products, developed using humanized polyclonal antibodies based on the Company’s platform to treat (i) botulism anti-toxin, (ii) pandemic influenza, or (iii) anti-fungal diseases. Amendment to Lease Agreement with Sanford Health On October 11, 2022, the Company entered into a Fourth Amendment (the “Fourth Amendment”) to the Amended and Restated Lease Agreement (as amended by the Fourth Amendment, the “Sanford Lease Agreement”) with Sanford Health, a South Dakota non-profit corporation (the “Sanford Health”). The Fourth Amendment, among other things, reduces the Company’s leased area under the Sanford Lease Agreement to 21,014 square feet. The Fourth Amendment reduces the rent due under the Sanford Lease Agreement to $ 531,024 (the “Annual Rent”), payable in monthly installments of $ 44,252 . Additionally, pursuant to the Fourth Amendment, the Company and Sanford Health agreed that for the period of October 1, 2022 to September 30, 2023, the Company’s obligation to pay the Annual Rent shall be abated and not required to be paid when normally due (the “Abated Rent”). In exchange for the Abated Rent, effective as of October 1, 2022, the Company issued to Sanford Health an 8 % unsecured, convertible promissory note (the “October Note”). Pursuant to the October Note, the Company shall pay the sum of $ 541,644 (the “Principal”) plus accrued and unpaid interest thereon on September 31, 2024 (the “Maturity Date”). Simple interest shall accrue on the outstanding Principal from and after the date of the October Note, and shall be payable on the Maturity Date. Sanford Health shall have the right, but not the obligation, to convert all or any part of the outstanding Principal of the October Note, together with any accrued and unpaid interest thereon to the date of such conversion, into such number of fully paid and non-assessable shares of the Company’s common stock, at any time and from time to time, prior to the later of the Maturity Date and the date on which the October Note is paid in full, subject to certain restrictions, at a conversion price per share of Common Stock equal to greater of (x) $ 1.50 and (y) the price at which the Company sells shares of common stock in any bona fide private or public equity financing prior to the Maturity Date. Nasdaq Notice Letter On October 5, 2022, the Company received the Notice Letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1), as the closing bid price for our common stock was below the $ 1.00 per share requirement for the last 30 consecutive business days. The Notice Letter stated that the Company has until the end of the Initial Compliance to regain compliance with the minimum bid price requirement, which Initial Compliance period is 180 calendar days, or until April 3, 2023 . If the Company does not regain compliance by the end of the Initial Compliance Period, the Company may apply for an additional compliance period as provided for in the Notice Letter. Nasdaq’s determination of whether the Company qualifies for an additional compliance period will depend on whether the Company will meet the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and a written notice of our intention to cure the deficiency during the additional compliance period by effecting a reverse stock split, if necessary. The Notice Letter has no immediate effect on the listing of our common stock on The Nasdaq Global Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company can regain compliance if the closing bid price of our common stock is at least $ 1.00 for a minimum of 10 consecutive business days. In the event that the Company does not regain compliance with Listing Rule 5450(a)(1) prior to the expiration of the Initial Compliance Period (or additional compliance period, if applicable), the Company will receive written notification that our securities are subject to delisting. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Basis of presentation | Basis of presentation The financial statements have been prepared in conformity with U.S. Generally Accepted Accounting Principles ("GAAP") and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, BCYP is treated as the “acquired” company and SAB Biotherapeutics is treated as the acquirer for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of SAB Biotherapeutics issuing stock for the net assets of BCYP, accompanied by a recapitalization. The net assets of BCYP are stated at historical cost, with no goodwill or other intangible assets recorded. SAB Biotherapeutics was determined to be the accounting acquirer based on the following predominant factors: • SAB Biotherapeutics’ shareholders have the largest portion of voting rights in the Company; • the Board and Management are primarily composed of individuals associated with SAB Biotherapeutics; • the operations of SAB comprise the ongoing operations of the Company. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of SAB Biotherapeutics. At the Closing Date, and subject to the terms and conditions of the Merger Agreement, each share of SAB Biotherapeutics common stock, par value $ 0.0001 per share, and each share of the SAB Biotherapeutics convertible preferred stock that was convertible into a share of SAB Biotherapeutics common stock at a one -to-one ratio, was converted into Common Stock equal to approximately 0.4653 (the "Exchange Ratio"). The shares and corresponding capital amounts and losses per share, prior to the Business Combination, have been retroactively restated based on shares reflecting the Exchange Ratio established in the Business Combination. |
Emerging Growth Company Status | Emerging growth company status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. |
Principles of consolidation | Principles of consolidation The accompanying consolidated financial statements include the results of the Company and its wholly owned subsidiaries, SAB Capra, LLC and Aurochs, LLC. Intercompany balances and transactions have been eliminated in consolidation. |
Significant risks and uncertainties | Significant risks and uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, the results of research and development efforts, clinical trial activities of the Company’s product candidates, the Company’s ability to obtain regulatory approval to market its product candidates, competition from products manufactured and sold or being developed by other companies, and the Company’s ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and obtaining and protecting intellectual property. Funding from government grants is not guaranteed to cover all costs, and additional funding may be needed to cover operational costs as the Company moves forward with our efforts to develop a commercially approved product. The company believes its existing cash reserves and anticipated cash receipts will not be sufficient to fund operations for the twelve months following the date these financials are made available for issuance. |
Use of estimates | Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements. The Company has used significant estimates in its determination of stock-based compensation assumptions, determination of the fair value of the Company’s common stock, determination of the fair value of the Private Placement Warrant liabilities, determination of the incremental borrowing rate (“IBR”) used in the calculation of the Company’s right of use assets and lease liabilities, and the valuation allowance on deferred tax assets. Actual amounts realized may differ from these estimates. |
Cash, cash equivalents, and restricted cash | Cash, cash equivalents, and restricted cash Cash equivalents include short-term, highly liquid instruments, consisting of money market accounts and short-term investments with original maturities at the date of purchase of 90 days or less. Amounts held in escrow by the Company pursuant to the Forward Share Purchase Agreement were reported as restricted cash on the consolidated balance sheet as of December 31, 2021. There were no amounts held in escrow by the Company pursuant to the Forward Share Purchase Agreement as of September 30, 2022. The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the consolidated statements of cash flows is as follows: September 30, September 30, Cash and cash equivalents $ 8,332,188 $ 10,750,762 Restricted cash — — Total cash, cash equivalents, and restricted cash $ 8,332,188 $ 10,750,762 |
Accounts receivable | Accounts receivable Accounts receivable are carried at original invoice amount, less an allowance for doubtful accounts. The Company estimates an allowance for doubtful accounts for potential credit losses that are expected to be incurred, based on management’s assessment of the collectability of specific accounts, the aging of the accounts receivable, historical information and other currently available evidence. Receivables are written off when deemed uncollectible. To date, no receivables have been written off. The Company had no allowance for doubtful accounts as of September 30, 2022 and December 31, 2021 . |
Concentration of credit risk | Concentration of credit risk The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to credit risk is reduced by placing such deposits in high credit quality federally insured financial institutions. The Company received 100 % of its total revenue through grants from government organizations during the three and nine months ended September 30, 2022 and 2021 . |
Lease liabilities and right-of-use assets | Lease liabilities and right-of-use assets The Company is party to certain contractual arrangements for equipment, lab space, and an animal facility, which meet the definition of leases under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 842, Leases (“ASC 842”). In accordance with ASC 842, the Company recorded right-of-use assets and related lease liabilities for the present value of the lease payments over the lease terms. The Company’s IBR was used in the calculation of its right-of-use assets and lease liabilities. The Company elected not to apply the recognition requirements of ASC 842 to short-term leases, which are deemed to be leases with a lease term of twelve months or less. Instead, the Company recognized lease payments in the Consolidated Statements of Operations on a straight-line basis over the lease term and variable payments in the period in which the obligation for these payments was incurred. The Company elected this policy for all classes of underlying assets. |
Research and development expenses | Research and development expenses Expenses incurred in connection with research and development activities are expensed as incurred. These include licensing fees to use certain technology in the Company’s research and development projects, fees paid to consultants and various entities that perform certain research and testing on behalf of the Company, and expenses related to salaries, benefits, and stock-based compensation granted to employees in research and development functions. During the three and nine months ended September 30, 2022 and 2021, the Company had contracts with multiple contract research organizations (“CRO”) to complete studies as part of research grant agreements. In the case of SAB-185, the CRO has been contracted and paid by the US government—as of September 30, 2022 there is no active CRO engaged by the Company in work on SAB-185. For SAB-176, PPD Development, LP acting as the CRO oversaw the Phase 1 safety study. The terms of that agreement are subject to confidentiality, and the status of the agreement is that it is current, in good standing and approxi mately 90 % of the contract has been paid as of September 30, 2022. SAB has also contracted with hVIVO Services Limited to conduct the Phase 2a influenza study on SAB-176. The terms of that agreement are subject to confidentiality, and the status of the agreement is that it is current, in good standing and approximate ly 90 % of the co ntract has been paid as of September 30, 2022 . |
Equipment | Equipment The Company records equipment at cost less depreciation. Depreciation is calculated using straight-line methods over the following estimated useful lives: Animal facility equipment 7 years Laboratory equipment 7 years Leasehold improvements Shorter of asset life or lease term Office furniture & equipment 5 years Vehicles 5 years Repairs and maintenance expenses are expensed as incurred. |
Impairment of long-lived assets | Impairment of long-lived assets The Company reviews the recoverability of long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. If necessary, the Company compares the estimated undiscounted future net cash flows to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known. The Company believes that long-lived assets are recoverable, and no impairment was deemed necessary, during the three and nine months ended September 30, 2022 and 2021 . |
Stock-based compensation | Stock-based compensation FASB ASC Topic 718, Compensation – Stock Compensation , prescribes accounting and reporting standards for all share-based payment transactions in which employee and non-employee services are acquired. The Company recognizes compensation cost relating to stock-based payment transactions using a fair-value measurement method, which requires all stock-based payments to employees, directors, and non-employee consultants, including grants of stock options, to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. Prior to the Business Combination, the grant date fair value of the Company's common stock was typically determined by the Company's board of directors with the assistance of management and a third-party valuation specialist. Subsequent to the Business Combination, the board of directors elected to determine the fair value of our post-merger common stock based on the closing market price at closing on the date of grant. In determining the fair value of stock-based awards, the Company utilizes the Black-Scholes option-pricing model, which uses both historical and current market data to estimate fair value. The Black-Scholes option-pricing model incorporates various assumptions, such as the value of the underlying common stock, the risk-free interest rate, expected volatility, expected dividend yield, and expected life of the options. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. No awards may have a term in excess of ten years. Forfeitures are recorded when they occur. Stock-based compensation expense is classified in the consolidated statements of operations based on the function to which the related services are provided. The company recognizes stock-based compensation expense over the expected term. |
Income taxes | Income taxes Deferred income taxes reflect future tax effects of temporary differences between the tax and financial reporting basis of the Company’s assets and liabilities measured using enacted tax laws and statutory tax rates applicable to the periods when the temporary differences will affect taxable income. When necessary, deferred tax assets are reduced by a valuation allowance, to reflect realizable value, and all deferred tax balances are reported as long-term on the consolidated balance sheet. Accruals are maintained for uncertain tax positions, as necessary. Income tax expense includes the current tax liability from operations and the change in deferred income taxes during the year. Current tax liabilities or receivables are recognized for estimated income tax payable and/or refundable for the current year. The Company uses a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The Company has elected to treat interest and penalties related to income taxes, to the extent they arise, as a component of income taxes. |
Revenue recognition | Revenue recognition The Company’s revenue is primarily generated through grants from government and other (non-government) organizations. Grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities , and that the grants are not within the scope of ASC 606, Revenue from Contracts with Customers , as the organizations providing the grants do not meet the definition of a customer. Expenses for grants are tracked by using a project code specific to the grant, and the employees also track hours worked by using the project code. |
Comprehensive income (loss) | Comprehensive income (loss) The Company had no items of comprehensive income (loss) other than its net income (loss). |
Litigation | Litigation From time to time, the Company is involved in legal proceedings, investigations and claims generally incidental to its normal business activities. In accordance with U.S. GAAP, the Company accrues for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal costs in connection with loss contingencies are expensed as incurred. |
Earnings per share | Earnings per share In accordance with ASC 260, Earnings per Share (“ASC 260”), basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding during the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding for the period including potential dilutive common shares such as stock options. |
Segment reporting | Segment reporting In accordance with ASC 280, Segment Reporting , the Company’s business activities are organized into one reportable segment, as only the Company’s operating results in their entirety are regularly reviewed by the Company’s chief operating decision maker to make decisions about resources to be allocated and to assess performance. |
Common stock valuations | Common stock valuations Prior to the Business Combination, the Company was required to periodically estimate the fair value of its common stock with the assistance of an independent third-party valuation firm, as discussed above, when issuing stock options and computing estimated stock-based compensation expense. The assumptions underlying these valuations represented the Company's best estimates, which involved inherent uncertainties and the application of significant levels of judgment. In order to determine the fair value of its common stock, the Company considered, among other items, previous transactions involving the sale of our securities, our business, financial condition and results of operations, economic and industry trends, the market performance of comparable publicly traded companies, and the lack of marketability of our common stock. Subsequent to the Business Combination, the Company now determines the fair value of common stock based on the closing market price at closing on the date of grant. Compensation expense related to stock-based transactions is measured and recognized in the financial statements at fair value of the post-merger common stock based on the closing market price at closing on the date of grant. Stock-based compensation expense is measured at the grant date based on the fair value of the equity award and is recognized as expense over the requisite service period, which is generally the vesting period, on the straight-line method. The Company estimates the fair value of each stock option award on the date of grant using the Black-Scholes option-pricing model. Determining the fair value of stock option awards at the grant date requires judgment, including estimating the expected volatility, expected term, risk-free interest rate, and expected dividends. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash | The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the consolidated statements of cash flows is as follows: September 30, September 30, Cash and cash equivalents $ 8,332,188 $ 10,750,762 Restricted cash — — Total cash, cash equivalents, and restricted cash $ 8,332,188 $ 10,750,762 |
Schedule of Estimated Useful Lives | The Company records equipment at cost less depreciation. Depreciation is calculated using straight-line methods over the following estimated useful lives: Animal facility equipment 7 years Laboratory equipment 7 years Leasehold improvements Shorter of asset life or lease term Office furniture & equipment 5 years Vehicles 5 years |
Earnings per share (Tables)
Earnings per share (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings per Share | The following is a reconciliation of the numerator and denominator used to calculate basic earnings per share and diluted earnings per share for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Calculation of basic and diluted loss per share Net loss attributable to the Company’s shareholders $ ( 7,076,068 ) $ ( 4,061,190 ) $ ( 10,866,209 ) $ ( 5,593,035 ) Weighted-average common shares outstanding – 43,030,885 25,973,406 43,042,379 25,973,406 Net loss per share, basic and diluted $ ( 0.16 ) $ ( 0.16 ) $ ( 0.25 ) $ ( 0.22 ) |
Summary of Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss per Share | The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Stock options and awards 1,004,845 2,570,978 2,181,361 2,077,499 Common stock warrants 5,958,600 — 5,958,600 — Earnout Shares (1) 10,491,937 — 10,491,937 — Contingently issuable Earnout Shares from unexercised 1,508,063 — 1,508,063 — Total 18,963,445 2,570,978 20,139,961 2,077,499 (1) As the Earnout shares are subject to certain vesting requirements not satisfied as of the three and nine months ended September 30, 2022 , the Earnout Shares held in escrow are excluded from calculating both basic and diluted earnings per share. |
Equipment (Tables)
Equipment (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Property, Plant and Equipment [Line Items] | |
Schedule of Construction-in-Progress | As of September 30, 2022 and December 31, 2021, the Company’s equipment was as follows: September 30, December 31, Laboratory equipment $ 8,801,250 $ 7,431,988 Animal facility 8,357,667 8,357,667 Animal facility equipment 1,141,213 1,253,879 Construction-in-progress 404,976 4,608,778 Leasehold improvements 9,280,795 5,700,364 Vehicles 192,683 135,593 Office furniture and equipment 1,233,038 46,202 Total Property, plant and equipment, gross 29,411,622 27,534,471 Less: accumulated depreciation and amortization ( 5,379,714 ) ( 3,220,016 ) Property, plant and equipment, net $ 24,031,908 $ 24,314,455 |
Construction-in-Progress [Member] | |
Property, Plant and Equipment [Line Items] | |
Schedule of Construction-in-Progress | The Company has several ongoing construction projects related to the expansion of its operating capacity. As of September 30, 2022 and December 31, 2021, the Company’s construction-in-progress was as follows: September 30, December 31, New office space at Headquarters $ 14,859 $ 11,183 Laboratory space at Headquarters — 2,506,482 Laboratory equipment at Headquarters 171,781 246,801 IT equipment at Headquarters 80,525 212,209 Software 137,811 137,811 Bioreactors — 1,280,728 Other — 213,564 Total construction-in-progress $ 404,976 $ 4,608,778 |
Leases (Tables)
Leases (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Leases [Abstract] | |
Estimated Useful Lives of Finance Lease Assets | Animal Facility 40 years Equipment 3 – 7 years Land Indefinite |
Schedule of Operating and Finance Leases Discount Rate | The Company’s weighted-average remaining lease term and weighted-average discount rate for operating and finance leases as of September 30, 2022 are: Operating Finance Weighted-average remaining lease term 1.69 years 16.13 years Weighted-average discount rate 4.78 % 7.72 % |
Schedule of Undiscounted Future Minimum Lease Payments | The table below reconciles the undiscounted future minimum lease payments under non-cancelable leases with terms of more than one year to the total lease liabilities recognized on the consolidated balance sheet as of September 30, 2022: Operating Finance 2022 - remaining $ 315,726 $ 110,994 2023 1,197,025 406,339 2024 535,944 401,496 2025 — 401,496 2026 — 401,496 Thereafter — 4,784,494 Undiscounted future minimum lease payments 2,048,695 6,506,315 Less: Amount representing interest payments ( 73,058 ) ( 2,702,883 ) Total lease liabilities 1,975,637 3,803,432 Less current portion ( 1,212,862 ) ( 140,891 ) Noncurrent lease liabilities $ 762,775 $ 3,662,541 |
Accrued Expenses and Other Cu_2
Accrued Expenses and Other Current Liabilities (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses and Other Current Liabilities | As of September 30, 2022 and December 31, 2021, accrued expenses and other current liabilities consisted of the following: September 30, December 31, Accrued vacation $ 563,726 $ 552,629 Accrued payroll 211,563 674,858 Accrued construction-in-progress 14,859 548,988 Accrued supplies 391,906 709,027 Accrued consulting 67,497 179,082 Accrued clinical trial expense 343,766 423,634 Accrued outside laboratory services 675,064 128,752 Accrued bonus & severance 1,793,676 1,804,288 Accrued contract manufacturing — 1,000,824 Accrued legal 720,154 833,646 Accrued financing fees payable 5,123,500 5,100,000 Accrued franchise tax payable 82,501 216,251 Other accrued expenses 250,000 283,909 $ 10,238,212 $ 12,455,888 |
Stock Option Plans (Tables)
Stock Option Plans (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Summary of Stock Options | Stock option activity for employees and non-employees under the Equity Compensation Plans for the nine months ended September 30, 2022 was as follows: Options Weighted Weighted Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding options, December 31, 2021 5,107,672 $ 2.44 5.78 $ 28,948,535 Granted 2,934,051 $ 1.54 Forfeited ( 503,274 ) $ 4.51 Exercised ( 90,264 ) $ 0.85 Expired ( 990 ) $ 4.97 Outstanding options, September 30, 2022 7,447,195 $ 1.97 6.27 $ 353,850 Options vested and exercisable, September 30, 2022 4,057,684 $ 1.47 3.47 $ 353,850 |
Summary of Assumptions Used to Calculate Estimated Fair Value of Stock Options | The estimated fair value of stock options granted to employees and consultants during the three and nine months ended September 30, 2022 and 2021, were calculated using the Black-Scholes option-pricing model using the following assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Expected volatility 97.4 % * 78.0 - 97.4 % 75.9 - 104.3 % Weighted-average volatility 97.4 % * 94.1 % 98.1 % Expected dividends — % * — % — % Expected term (in years) 5.77 - 6.08 * 5.50 - 6.08 6.25 Risk-free rate 3.55 - 3.56 % * 1.38 - 3.56 % 0.14 - 0.59 % * No options were granted during the three months ended September 30, 2021 . |
Summary of Restricted Stock | Stock award activity for employees and non-employees under the Equity Compensation Plans for the nine months ended September 30, 2022 was as follows: Number of shares Weighted Unvested as of December 31, 2021 — $ — Granted 350,000 $ 1.72 Vested — $ — Forfeited — $ — Unvested as of September 30, 2022 350,000 $ 1.72 |
Schedule of Stock-based Compensation Expense | Stock-based compensation expense for the three and nine months ended September 30, 2022 and 2021 was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Research and development $ 165,607 $ 211,841 $ 683,646 $ 726,245 General and administrative 412,596 668,823 1,362,018 936,965 Total $ 578,203 $ 880,664 $ 2,045,664 $ 1,663,210 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | The following tables present information about the Company's assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: As of September 30, 2022 Total Quoted Significant Significant Liabilities: Public Warrant liability $ 345,000 $ 345,000 $ — $ — Private Placement Warrant liability 12,516 — — 12,516 Total $ 357,516 $ 345,000 $ — $ 12,516 As of December 31, 2021 Total Quoted Significant Significant Liabilities: Public Warrant liability $ 10,292,500 $ 10,292,500 $ — $ — Private Placement Warrant liability 427,630 — — 427,630 Total $ 10,720,130 $ 10,292,500 $ — $ 427,630 |
Summary of Changes in Level 3 Fair Value Measurements | The following table provides a summary of the changes in our Level 3 fair value measurements: September 30, Balance, December 31, 2021 $ 427,630 Change in fair value of Private Placement Warrant liability ( 317,072 ) Balance, March 31, 2022 $ 110,558 Change in fair value of Private Placement Warrant liability ( 62,580 ) Balance, June 30, 2022 $ 47,978 Change in fair value of Private Placement Warrant liability $ ( 35,462 ) Balance, September 30, 2022 $ 12,516 |
Schedule of Key Inputs into Monte Carlo Simulation | The key inputs into the valuations as of September 30, 2022 and December 31, 2021 were as follows: September 30, December 31, Risk-free interest rate 4.15 % 1.24 % Expected term remaining (years) 4.06 4.81 Implied volatility 76.5 % 43.0 % Closing common stock price on the measurement date $ 0.70 $ 7.81 |
Nature of Business (Details Nar
Nature of Business (Details Narrative) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Accumulated deficit | $ 39,995,152 | $ 29,128,951 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details Narrative) | 3 Months Ended | 9 Months Ended | ||||
Sep. 30, 2022 USD ($) $ / shares | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) Segment $ / shares | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) $ / shares | Oct. 22, 2021 $ / shares shares | |
Product Information [Line Items] | ||||||
Common stock par value | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||
Amounts held in escrow | $ 0 | $ 0 | $ 6,338,306 | |||
Allowance for doubtful accounts | 0 | 0 | 0 | |||
Impairment of long lived assets | $ 0 | $ 0 | $ 0 | $ 0 | ||
Number of reporting segments | Segment | 1 | |||||
Big Cypress Acquisition Corp [Member] | ||||||
Product Information [Line Items] | ||||||
Common stock par value | $ / shares | $ 0.0001 | |||||
Preferred stock to common stock exchange ratio | 0.4653 | |||||
Number of common shares issued for each share of convertible preferred | shares | 1 | |||||
Contract Research Organizations [Member] | ||||||
Product Information [Line Items] | ||||||
Goods standing percentage | 90% | |||||
HVIVI Services [Member] | ||||||
Product Information [Line Items] | ||||||
Goods standing percentage | 90% | |||||
Government [Member] | ||||||
Product Information [Line Items] | ||||||
Revenue percentage | 100% | 100% | 100% | 100% | ||
Forward Share Purchase Agreement [Member] | ||||||
Product Information [Line Items] | ||||||
Amounts held in escrow | $ 6,300,000 |
Schedule of Reconciliation of C
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Dec. 31, 2020 |
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 8,332,188 | $ 33,206,712 | $ 10,750,762 | |
Restricted cash | 0 | 6,338,306 | ||
Total cash, cash equivalents and restricted cash shown in the statement of cash flows | $ 8,332,188 | $ 39,545,018 | $ 10,750,762 | $ 12,610,383 |
Schedule of Estimated Useful Li
Schedule of Estimated Useful Lives (Details) | 9 Months Ended |
Sep. 30, 2022 | |
Property, Plant and Equipment [Line Items] | |
Equipment useful life | 3 years |
Animal Facility Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Equipment useful life | 7 years |
Laboratory Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Equipment useful life | 7 years |
Leasehold Improvements [Member] | |
Property, Plant and Equipment [Line Items] | |
Equipment description | Shorter of asset life or lease term |
Office Furniture and Equipment [Member] | |
Property, Plant and Equipment [Line Items] | |
Equipment useful life | 5 years |
Vehicles [Member] | |
Property, Plant and Equipment [Line Items] | |
Equipment useful life | 5 years |
New Accounting Standards (Detai
New Accounting Standards (Details Narrative) | Sep. 30, 2022 |
ASU 2021-04 [Member] | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Change in Accounting Principle, Accounting Standards Update, Adopted [true false] | true |
Change in Accounting Principle, Accounting Standards Update, Adoption Date | Jan. 01, 2022 |
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] | true |
ASU 2021-05 [Member] | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Change in Accounting Principle, Accounting Standards Update, Adopted [true false] | true |
Change in Accounting Principle, Accounting Standards Update, Adoption Date | Jan. 01, 2022 |
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] | true |
ASU 2021-10 [Member] | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Change in Accounting Principle, Accounting Standards Update, Adopted [true false] | true |
Change in Accounting Principle, Accounting Standards Update, Adoption Date | Jan. 01, 2022 |
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] | true |
Reverse Recapitalization and _2
Reverse Recapitalization and Business Combination (Details Narrative) - USD ($) | 9 Months Ended | 12 Months Ended | ||
Oct. 22, 2021 | Oct. 12, 2021 | Sep. 30, 2022 | Dec. 31, 2021 | |
Business Acquisition [Line Items] | ||||
Common stock par value | $ 0.0001 | $ 0.0001 | ||
Net assets acquired and adjusted to forward share purchase liability | $ 13,098,599 | $ 6,338,306 | ||
Forward share purchase liability settlement amount | $ 817,060 | |||
Restricted cash | $ 0 | 6,338,306 | ||
First Earnout [Member] | ||||
Business Acquisition [Line Items] | ||||
Percentage of earn out shares to be released | 25% | |||
Period to issue earn out shares immediately closing of acquisition | 5 years | |||
Threshold VWAP | $ 15 | |||
Threshold VWAP trading days | 20 days | |||
Threshold VWAP consecutive trading days | 30 days | |||
Second Earnouts [Member] | ||||
Business Acquisition [Line Items] | ||||
Percentage of earn out shares to be released | 25% | |||
Period to issue earn out shares immediately closing of acquisition | 5 years | |||
Threshold VWAP | $ 20 | |||
Threshold VWAP trading days | 20 days | |||
Threshold VWAP consecutive trading days | 30 days | |||
Third Earnouts [Member] | ||||
Business Acquisition [Line Items] | ||||
Percentage of earn out shares to be released | 25% | |||
Period to issue earn out shares immediately closing of acquisition | 5 years | |||
Threshold VWAP | $ 25 | |||
Threshold VWAP trading days | 20 days | |||
Threshold VWAP consecutive trading days | 30 days | |||
Fourth Earnouts [Member] | ||||
Business Acquisition [Line Items] | ||||
Percentage of earn out shares to be released | 25% | |||
Period to issue earn out shares immediately closing of acquisition | 5 years | |||
Threshold VWAP | $ 30 | |||
Threshold VWAP trading days | 20 days | |||
Threshold VWAP consecutive trading days | 30 days | |||
Forward Share Purchase Agreement [Member] | ||||
Business Acquisition [Line Items] | ||||
Sale of stock, number of shares issued in transaction | 1,390,000 | |||
Sale of stock, price per share | $ 10.10 | |||
Sale of stock description | Further, BCYP shall purchase the remaining shares held by Radcliffe not sold in the open market in excess of the Market Sales Price at the later of (a) the 90th day after the closing of the Business Combination, or (b) the first business day following the 95th day after the closing of the Business Combination if BCYP directs Radcliffe to sell shares | |||
Restricted cash | 6,300,000 | |||
Payment for repurchase common stock | $ 5,500,000 | |||
Repurchase of common stock shares | 546,658 | |||
Big Cypress Acquisition Corp [Member] | ||||
Business Acquisition [Line Items] | ||||
Common stock par value | $ 0.0001 | |||
VWAP threshold period for earn out shares | 5 years | |||
Big Cypress Acquisition Corp [Member] | Common Stock [Member] | ||||
Business Acquisition [Line Items] | ||||
Number of shares issued or issuable to acquire entity | 36,465,343 | |||
VWAP threshold period for earn out shares | 5 years | |||
Contingent right to receive pro rate portion of earn out shares | 12,000,000 | |||
Contingent right earn out shares contingently issuable upon future satisfaction | 1,508,063 | |||
Contingent right earn out shares, issued | 10,491,937 | |||
Contingent right earn out shares, outstanding | 10,491,937 | |||
Contingent right to receive pro rate portion of earn out shares, fair value | $ 101,300,000 |
Revenue (Details Narrative)
Revenue (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 24 Months Ended | 48 Months Ended | ||||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Aug. 31, 2021 | Mar. 31, 2021 | Jul. 31, 2021 | Dec. 31, 2021 | |
Disaggregation of Revenue [Line Items] | ||||||||
Grant income | $ 731,248 | $ (70,836) | $ 10,191,399 | $ 455,936 | ||||
Accounts receivable, net | 12,942,037 | 12,942,037 | $ 8,010,708 | |||||
Government [Member] | ||||||||
Disaggregation of Revenue [Line Items] | ||||||||
Revenue | 3,600,000 | 14,600,000 | 21,700,000 | 49,800,000 | ||||
Grant | $ 1,500,000 | |||||||
Grant income | $ 150,000 | 13,000 | 281,000 | 41,000 | ||||
Remaining grant | 533,000 | |||||||
Contract cost | $ 204,000,000 | |||||||
Revenue remaining percentage | 9% | 9% | ||||||
Accounts receivable, net | $ 12,700,000 | $ 12,700,000 | ||||||
Government [Member] | National Institute of Health [Member] | ||||||||
Disaggregation of Revenue [Line Items] | ||||||||
Grant | $ 1,400,000 | |||||||
Grant income | 0 | 306,000 | 30,000 | 457,000 | ||||
Remaining grant | 184,000 | |||||||
Government [Member] | Geneva Foundation [Member] | ||||||||
Disaggregation of Revenue [Line Items] | ||||||||
Grant | $ 2,700,000 | |||||||
Grant income | 39,000 | 24,000 | 88,000 | 72,000 | ||||
Remaining grant | 1,400,000 | |||||||
Government [Member] | Advanced Technology International [Member] | ||||||||
Disaggregation of Revenue [Line Items] | ||||||||
Grant | 25,000,000 | |||||||
Grant income | $ 3,400,000 | $ 14,300,000 | $ 21,300,000 | $ 49,200,000 |
Schedule of Earnings per Share
Schedule of Earnings per Share (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Earnings Per Share [Abstract] | ||||
Net loss attributable to the Company's shareholders | $ (7,076,068) | $ (4,061,190) | $ (10,866,209) | $ (5,593,035) |
Weighted-average common shares outstanding – basic | 43,030,885 | 25,973,406 | 43,042,379 | 25,973,406 |
Weighted-average common shares outstanding - diluted | 43,030,885 | 25,973,406 | 43,042,379 | 25,973,406 |
Net loss per share, basic | $ (0.16) | $ (0.16) | $ (0.25) | $ (0.22) |
Net loss per share, diluted | $ (0.16) | $ (0.16) | $ (0.25) | $ (0.22) |
Summary of Anti-dilutive Shares
Summary of Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss per Share (Details) - shares | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of earnings per share, Total | 18,963,445 | 2,570,978 | 20,139,961 | 2,077,499 |
Stock Options and Awards [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of earnings per share, Total | 1,004,845 | 2,570,978 | 2,181,361 | 2,077,499 |
Common Stock Warrants [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of earnings per share, Total | 5,958,600 | 5,958,600 | ||
Earnout Shares [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of earnings per share, Total | 10,491,937 | 10,491,937 | ||
Contingently Issuable Earnout Shares from Unexercised Rollover Options [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of earnings per share, Total | 1,508,063 | 1,508,063 |
Schedule of Equipment (Details)
Schedule of Equipment (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Property, Plant and Equipment [Line Items] | ||
Total Property, plant and equipment, gross | $ 29,411,622 | $ 27,534,471 |
Less: accumulated depreciation and amortization | (5,379,714) | (3,220,016) |
Property, plant and equipment, net | 24,031,908 | 24,314,455 |
Laboratory Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total Property, plant and equipment, gross | 8,801,250 | 7,431,988 |
Animal Facility [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total Property, plant and equipment, gross | 8,357,667 | 8,357,667 |
Animal Facility Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total Property, plant and equipment, gross | 1,141,213 | 1,253,879 |
Construction-in-Progress [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total Property, plant and equipment, gross | 404,976 | 4,608,778 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total Property, plant and equipment, gross | 9,280,795 | 5,700,364 |
Vehicles [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total Property, plant and equipment, gross | 192,683 | 135,593 |
Office Furniture and Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total Property, plant and equipment, gross | $ 1,233,038 | $ 46,202 |
Equipment (Details Narrative)
Equipment (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Property, Plant and Equipment [Abstract] | ||||
Depreciation and amortization expense | $ 885,195 | $ 369,366 | $ 2,270,621 | $ 868,630 |
Property, plant and equipment, useful life | 3 years | |||
Acquisition costs | $ 5,000 |
Schedule of Construction-in-Pro
Schedule of Construction-in-Progress (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Property, Plant and Equipment [Line Items] | ||
Total construction-in-progress | $ 404,976 | $ 4,608,778 |
Construction in Progress [Member] | New Office Space [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total construction-in-progress | 14,859 | 11,183 |
Construction in Progress [Member] | Laboratory Space [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total construction-in-progress | 2,506,482 | |
Construction in Progress [Member] | Laboratory Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total construction-in-progress | 171,781 | 246,801 |
Construction in Progress [Member] | IT Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total construction-in-progress | 80,525 | 212,209 |
Construction in Progress [Member] | Software [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total construction-in-progress | $ 137,811 | 137,811 |
Construction in Progress [Member] | Bioreactors [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total construction-in-progress | 1,280,728 | |
Construction in Progress [Member] | Other [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Total construction-in-progress | $ 213,564 |
Leases (Details Narrative)
Leases (Details Narrative) | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||||
Mar. 31, 2019 USD ($) Agreement | Dec. 31, 2018 USD ($) gal | Jul. 31, 2018 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) Period | Sep. 30, 2021 USD ($) | |
Lessee, Lease, Description [Line Items] | |||||||
Finance lease right of use asset amortization | $ 25,000 | $ 41,000 | $ 98,000 | $ 124,000 | |||
Finance lease interest expense | 71,000 | 78,000 | 214,000 | 228,000 | |||
Operating lease payments | 309,000 | 285,000 | 930,000 | 836,000 | |||
Finance lease cash payments | $ 103,000 | 131,000 | $ 334,000 | 372,000 | |||
Ruby Cell Analyzer [Member] | |||||||
Lessee, Lease, Description [Line Items] | |||||||
Finance lease cash payments | $ 807 | ||||||
Finance lease term | 5 years | ||||||
Finance lease incorporation period | 2018-07 | ||||||
Purchase of assets | $ 1 | ||||||
Dakota Ag Properties [Member] | |||||||
Lessee, Lease, Description [Line Items] | |||||||
Finance lease cash payments | $ 33,458 | ||||||
Lessee finance lease interest rate | 8% | ||||||
Finance lease term | 20 years | ||||||
Finance lease incorporation period | 2018-12 | ||||||
Lease payback construction cost | $ 4,000,000 | ||||||
Equipment [Member] | |||||||
Lessee, Lease, Description [Line Items] | |||||||
Finance lease propane tank volume | gal | 12,000 | ||||||
Finance lease cash payments | $ 8,199 | ||||||
Finance lease term | 5 years | ||||||
Finance lease incorporation period | 2018-12 | ||||||
Laboratory Equipment [Member] | |||||||
Lessee, Lease, Description [Line Items] | |||||||
Finance lease cash payments | $ 5,956 | ||||||
Finance lease term | 3 years | ||||||
Finance lease incorporation period | 2019-03 | ||||||
Purchase of assets | $ 1 | ||||||
Number of lease agreements | Agreement | 2 | ||||||
Lab Space [Member] | |||||||
Lessee, Lease, Description [Line Items] | |||||||
Operating lease commencement period | 2014-06 | ||||||
Operating lease expired period | 2019-06 | ||||||
Operating lease amended expired period | 2024-08 | ||||||
Operating lease amended period | 2022-07 | ||||||
Operating lease existence of option to extend [true false] | false | ||||||
Operating lease payments per month | $ 66,993 | ||||||
Lease termination description | This lease can be terminated with one year advance written notice. | ||||||
Operating lease liablity discount rate | 4.54% | 4.54% | |||||
Office, Laboratory, and Warehouse [Member] | |||||||
Lessee, Lease, Description [Line Items] | |||||||
Operating lease commencement period | 2020-11 | ||||||
Operating lease existence of option to extend [true false] | true | ||||||
Operating lease number of option to extended additional period | Period | 3 | ||||||
Operating lease option to extended additional period | 3 years | ||||||
Operating lease liablity discount rate | 4.83% | 4.83% | |||||
Operating lease term | 3 years | 3 years | |||||
Lease cost per month | $ 38,872 | ||||||
Barn Space [Member] | |||||||
Lessee, Lease, Description [Line Items] | |||||||
Operating lease commencement period | 2020-04 | ||||||
Operating lease liablity discount rate | 4.08% | 4.08% | |||||
Operating lease term | 2 years | 2 years | |||||
Lease cost per month | $ 678 | 665 | |||||
Research and Development Expense [Member] | |||||||
Lessee, Lease, Description [Line Items] | |||||||
Operating lease expense | $ 304,000 | $ 268,000 | $ 889,000 | $ 789,000 |
Leases - Estimated Useful Lives
Leases - Estimated Useful Lives of Finance Lease Assets (Details) | 9 Months Ended |
Sep. 30, 2022 | |
Lessee, Lease, Description [Line Items] | |
Estimated useful lives of the finance lease assets | 3 years |
Animal Facilty [Member] | |
Lessee, Lease, Description [Line Items] | |
Estimated useful lives of the finance lease assets | 40 years |
Equipment [Member] | |
Lessee, Lease, Description [Line Items] | |
Estimated useful lives of the finance lease assets | 7 years |
Equipment [Member] | Minimum [Member] | |
Lessee, Lease, Description [Line Items] | |
Estimated useful lives of the finance lease assets | 3 years |
Equipment [Member] | Maximum [Member] | |
Lessee, Lease, Description [Line Items] | |
Estimated useful lives of the finance lease assets | 7 years |
Land [Member] | |
Lessee, Lease, Description [Line Items] | |
Estimated useful lives of the finance lease assets | Indefinite |
Leases - Schedule of Operating
Leases - Schedule of Operating and Finance Leases Discount Rate (Details) | Sep. 30, 2022 |
Leases [Abstract] | |
Weighted-average remaining operating lease term | 1 year 8 months 8 days |
Weighted-average remaining finance lease term | 16 years 1 month 17 days |
Weighted-average operating lease discount rate | 4.78% |
Weighted-average finance discount rate | 7.72% |
Leases - Schedule of Undiscount
Leases - Schedule of Undiscounted Future Minimum Lease Payments (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Operating Lease | ||
Operating Lease 2022 - remaining | $ 315,726 | |
Operating Lease 2023 | 1,197,025 | |
Operating Lease 2024 | 535,944 | |
Operating lease Undiscounted future minimum lease payments | 2,048,695 | |
Less:Operating Lease Amount representing interest payments | (73,058) | |
Total Operating lease liabilities | 1,975,637 | |
Less current portion of Operating Lease | (1,212,862) | $ (1,142,413) |
Noncurrent Operating lease liabilities | 762,775 | 1,653,185 |
Finance Lease | ||
Finance Lease 2022 - remaining | 110,994 | |
Finance Lease 2023 | 406,339 | |
Finance Lease 2024 | 401,496 | |
Finance Lease 2025 | 401,496 | |
Finance Lease 2026 | 401,496 | |
Finance Leases Thereafter | 4,784,494 | |
Finance lease Undiscounted future minimum lease payments | 6,506,315 | |
Less: Finance lease Amount representing interest payments | (2,702,883) | |
Total finance lease liabilities | 3,803,432 | |
Less current portion of finance Lease | (140,891) | (161,050) |
Noncurrent finance lease liabilities | $ 3,662,541 | $ 3,762,430 |
Schedule of Accrued Expenses an
Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Payables and Accruals [Abstract] | ||
Accrued vacation | $ 563,726 | $ 552,629 |
Accrued payroll | 211,563 | 674,858 |
Accrued construction-in-progress | 14,859 | 548,988 |
Accrued supplies | 391,906 | 709,027 |
Accrued consulting | 67,497 | 179,082 |
Accrued clinical trial expense | 343,766 | 423,634 |
Accrued outside laboratory services | 675,064 | 128,752 |
Accrued bonus & severance | 1,793,676 | 1,804,288 |
Accrued contract manufacturing | 1,000,824 | |
Accrued legal | 720,154 | 833,646 |
Accrued financing fees payable | 5,123,500 | 5,100,000 |
Accrued franchise tax payable | 82,501 | 216,251 |
Other accrued expenses | 250,000 | 283,909 |
Total | $ 10,238,212 | $ 12,455,888 |
Notes Payable (Details Narrativ
Notes Payable (Details Narrative) - USD ($) | 1 Months Ended | 9 Months Ended | 12 Months Ended | ||
Apr. 30, 2020 | Sep. 30, 2021 | Dec. 31, 2017 | Sep. 30, 2022 | Dec. 31, 2021 | |
Short-Term Debt [Line Items] | |||||
Gain on extinguishment of debt | $ 665,596 | ||||
Tractor [Member] | |||||
Short-Term Debt [Line Items] | |||||
Interest rate | 3.60% | ||||
Loan payable | $ 25,013 | $ 25,013 | |||
Monthly payment of loan | $ 25,913 | ||||
Purchase of assets | $ 116,661 | ||||
PPP Loan [Member] | |||||
Short-Term Debt [Line Items] | |||||
Interest rate | 1% | ||||
Proceeds from bank loan | $ 661,612 | ||||
Debt instrument maturity month and year | 2022-04 | ||||
Gain on extinguishment of debt | $ 665,596 |
Preferred Stock (Details Narrat
Preferred Stock (Details Narrative) - USD ($) | 9 Months Ended | |||||
Sep. 30, 2022 | Dec. 31, 2021 | Oct. 22, 2021 | Oct. 21, 2021 | Sep. 30, 2019 | Aug. 31, 2019 | |
Class of Stock [Line Items] | ||||||
Shares authorized | 10,000,000 | 10,000,000 | 10,000,000 | 50,000,000 | ||
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||
Preferred stock, shares outstanding | 0 | 0 | 17,750,882 | 8,000,000 | ||
Preferred stock converted into common stock | 8,259,505 | |||||
Conversion Ratio Description | The effective conversion rate as of December 31, 2020 was 1:1. | |||||
Common Stock [Member] | ||||||
Class of Stock [Line Items] | ||||||
Gross proceed | $ 20,000,000 | |||||
Series A Preferred Stock [Member] | ||||||
Class of Stock [Line Items] | ||||||
Shares authorized | 6,615,000 | |||||
Preferred Stock, Par or Stated Value Per Share | $ 1 | |||||
Series A-1 Preferred Stock [Member] | ||||||
Class of Stock [Line Items] | ||||||
Shares authorized | 2,525,800 | |||||
Preferred Stock, Par or Stated Value Per Share | $ 1.88 | |||||
Series A-2 Preferred Stock [Member] | ||||||
Class of Stock [Line Items] | ||||||
Shares authorized | 4,039,963 | |||||
Preferred Stock, Par or Stated Value Per Share | $ 3 | |||||
Series A-2A Preferred Stock [Member] | ||||||
Class of Stock [Line Items] | ||||||
Shares authorized | 3,333,333 | |||||
Preferred Stock, Par or Stated Value Per Share | $ 3 | |||||
Preferred stock, redemption price per share | $ 5 | |||||
Series B Preferred Stock [Member] | ||||||
Class of Stock [Line Items] | ||||||
Shares authorized | 8,571,429 | |||||
Preferred Stock, Par or Stated Value Per Share | $ 3.50 |
Stock Option Plans (Details Nar
Stock Option Plans (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | |||||||
Jan. 01, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | Oct. 22, 2021 | Dec. 31, 2019 | Aug. 05, 2014 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||
Number of stock options Vested during the period | 108,611 | 120,626 | 314,380 | 351,974 | |||||
Weighted average grant date fair value of options granted | $ 0.57 | $ 0.78 | $ 5.21 | ||||||
Number of stock options granted | 0 | 2,934,051 | |||||||
Fair value of stock options vested during the period | $ 478 | $ 395 | $ 1,300 | $ 1,300 | |||||
Unrecognized compensation expense | 5,100 | $ 5,100 | |||||||
Unrecognized compensation expected to be recognized weighted-average period | 3 years 4 months 6 days | ||||||||
Restricted Stock [Member] | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||
Unrecognized compensation expected to be recognized weighted-average period | 3 years 8 months 15 days | ||||||||
Unrecognized compensation cost related to non-vested stock awards | $ 600 | $ 600 | |||||||
Stock Option Plan [Member] | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||
Number of shares authorized to issue under plan | 7,444,800 | 16,000,000 | 8,000,000 | ||||||
Omnibus Equity Incentive Plan [Member] | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||
Common stock reserved for future issuance | 11,869,746 | 11,869,746 | 11,000,000 | ||||||
Increase in common stock, capital shares reserved for future issuance | 869,746 | ||||||||
Common stock reserved for future issuance increased, percentage | 2% |
Summary of Stock Options (Detai
Summary of Stock Options (Details) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended |
Sep. 30, 2021 | Sep. 30, 2022 | Dec. 31, 2021 | |
Share-Based Payment Arrangement [Abstract] | |||
Number of Stock Options Outstanding, at Beginning of Period | 5,107,672 | ||
Number of Stock Options, Granted | 0 | 2,934,051 | |
Number of Stock Options, Forfeited | 503,274 | ||
Number of Stock Options, Exercised | 90,264 | ||
Number of Stock Option, Expired | 990 | ||
Number of Stock Options Outstanding, at End of Period | 7,447,195 | 5,107,672 | |
Options vested and exercisable at September 30, 2022 | 4,057,684 | ||
Weighted Average Exercise Price Per Share, at Beginning of Period | $ 2.44 | ||
Weighted Average Exercise Price Per Share, Granted | 1.54 | ||
Weighted Average Exercise Price Per Share, Forfeited | 4.51 | ||
Weighted Average Exercise Price Per Share, Exercised | 0.85 | ||
Weighted Average Exercise Price Per Share, Expired | 4.97 | ||
Weighted Average Exercise Price, at End of Period | 1.97 | $ 2.44 | |
Weighted Average Exercise Price vested and exercisable at September 30, 2022 | $ 1.47 | ||
Weighted-Average Remaining Contractual Life (in years), Options outstanding | 6 years 3 months 7 days | 5 years 9 months 10 days | |
Weighted-Average Remaining Contractual Life (in years), Options vested and exercisable at September 30, 2022 | 3 years 5 months 19 days | ||
Aggregate intrinsic value, outstanding | $ 353,850 | $ 28,948,535 | |
Aggregate Intrinsic Value, Options vested and exercisable at September 30, 2022 | $ 353,850 |
Summary of Assumptions Used to
Summary of Assumptions Used to Calculate Estimated Fair Value of Stock Option (Details) | 3 Months Ended | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
Expected volatility | 97.40% | ||
Expected volatility, minimum | 78% | 75.90% | |
Expected volatility, maximum | 97.40% | 104.30% | |
Weighted-average volatility | 97.40% | 94.10% | 98.10% |
Expected term (in years) | 6 years 3 months | ||
Risk-free rate, minimum | 3.55% | 1.38% | 0.14% |
Risk-free rate, maximum | 3.56% | 3.56% | 0.59% |
Minimum [Member] | |||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
Expected term (in years) | 5 years 9 months 7 days | 5 years 6 months | |
Maximum [Member] | |||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
Expected term (in years) | 6 years 29 days | 6 years 29 days |
Summary of Assumptions Used t_2
Summary of Assumptions Used to Calculate Estimated Fair Value of Stock Option (Parenthetical) (Details) - shares | 3 Months Ended | 9 Months Ended |
Sep. 30, 2021 | Sep. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | ||
Number of stock options granted | 0 | 2,934,051 |
Stock Option Plans - Summary of
Stock Option Plans - Summary of Restricted Stock (Details) - Restricted Stock [Member] | 9 Months Ended |
Sep. 30, 2022 $ / shares shares | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |
Number of shares, Granted | shares | 350,000 |
Number of unvested shares, End of Period | shares | 350,000 |
Weighted Average Grant Date Fair Value, Granted | $ / shares | $ 1.72 |
Weighted Average Grant Date Fair Value, End of Period | $ / shares | $ 1.72 |
Schedule of Stock-based Compens
Schedule of Stock-based Compensation Expense (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Total | $ 578,203 | $ 880,664 | $ 2,045,664 | $ 1,663,210 |
Research and Development Expense [Member] | ||||
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Total | 165,607 | 211,841 | 683,646 | 726,245 |
General and Administrative Expense [Member] | ||||
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Total | $ 412,596 | $ 668,823 | $ 1,362,018 | $ 936,965 |
Schedule of Fair Value, Assets
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Public Warrants Liability | $ 345,000 | $ 10,292,500 |
Private Placement Warrants Liability | 12,516 | 427,630 |
Fair value of liabilities | 357,516 | 10,720,130 |
Fair Value, Inputs, Level 1 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Public Warrants Liability | 345,000 | 10,292,500 |
Fair value of liabilities | 345,000 | 10,292,500 |
Fair Value, Inputs, Level 3 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Private Placement Warrants Liability | 12,516 | 427,630 |
Fair value of liabilities | $ 12,516 | $ 427,630 |
Summary of Changes in Level 3 F
Summary of Changes in Level 3 Fair Value Measurements (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2022 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||||
Fair value liabilities, Beginning balance | $ 427,630 | $ 427,630 | ||
Changes in fair value of Private Placement Warrant liability | $ (35,462) | $ (62,580) | (317,072) | |
Fair value of liabilities, Ending balance | $ 12,516 | $ 47,978 | $ 110,558 | $ 12,516 |
Fair Value Measurements (Detail
Fair Value Measurements (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Sep. 30, 2022 | Dec. 31, 2021 | |
Recurring [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Assets fair value disclosure | $ 0 | $ 0 | $ 0 |
Liabilities fair value disclosure | $ 0 | $ 0 | 0 |
Public Warrants [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Sale of stock description | Each whole Public Warrant entitles the holder to purchase one share of the Company's common stock at a price of $11.50 per share | ||
Warrant price | $ 0.01 | $ 0.01 | |
Redemption of warrants description | the reported last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a | ||
Warrants outstanding | 5,750,000 | 5,750,000 | |
Initial Measurement on the Closing Date | 6,300,000 | ||
Changes in fair value of Private Placement Warrant liability | $ (800,000) | $ (9,900,000) | $ 4,000,000 |
Public Warrants [Member] | Common Stock [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Share issued price | $ 11.50 | $ 11.50 | |
Private Placement Warrants [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Warrants outstanding | 208,600 | 208,600 |
Schedule of Key Inputs into Mon
Schedule of Key Inputs into Monte Carlo Simulation (Details) | Sep. 30, 2022 $ / shares | Dec. 31, 2021 $ / shares |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Initial measurement inputs, expected term remaining (years) | 4 years 21 days | 4 years 9 months 21 days |
Closing common stock price on the measurement date | $ 0.70 | $ 7.81 |
Risk-Free Interest Rate [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Initial measurement inputs | 0.0415 | 0.0124 |
Implied Volatility [Member] | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Initial measurement inputs | 0.765 | 0.430 |
Income Taxes (Details Narrative
Income Taxes (Details Narrative) - USD ($) $ in Millions | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | ||
Effective income tax rate | 0% | 0% |
TCJA amendments description | Starting in 2022, Tax Cuts and Jobs Act amendments to Internal Revenue Code Section 174 will no longer permit an immediate deduction for research and development expenditures in the tax year that such costs are incurred. The 2022 first quarter effective income tax rate was impacted by the Section 174 capitalization requirement combined with the restriction on net operating losses to only reduce taxable income by 80%. | |
Increase (decrease) in valuation allowance of deferred tax assets | $ 4.5 | |
Net operating losses to reduce taxable income, percentage | 80% |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Related Party Transaction [Line Items] | ||||
Consulting fees | $ 0 | $ 25,000 | ||
Lease payments | $ 309,000 | 285,000 | $ 930,000 | 836,000 |
Beneficial owners percentage | 5% | 5% | ||
Ownership interest percentage | 5% | 5% | ||
Dakota Ag Properties [Member] | ||||
Related Party Transaction [Line Items] | ||||
Lease and insurance payments | 67,000 | 301,000 | ||
Sanford Health Corporation [Member] | ||||
Related Party Transaction [Line Items] | ||||
Lease payments | $ 15,000 | $ 93,000 |
Employee Benefit Plan (Details
Employee Benefit Plan (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Retirement Benefits [Abstract] | ||||
Percentage of employee contribution matching contribution | 50% | 100% | ||
Percentage of employee contribution | 2% | 3% | ||
Employee contribution amount | $ 91,000 | $ 67,000 | $ 350,000 | $ 245,000 |
Joint Development Agreement (De
Joint Development Agreement (Details Narrative) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Jun. 30, 2019 USD ($) SquareFeet | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | |
Defined Benefit Plan Disclosure [Line Items] | ||||||
Lease payments | $ 309,000 | $ 285,000 | $ 930,000 | $ 836,000 | ||
Design costs expense | $ 7,352,978 | $ 15,070,265 | 29,300,405 | $ 46,535,671 | ||
University of South Dakota Research Park Inc [Member] | ||||||
Defined Benefit Plan Disclosure [Line Items] | ||||||
Number of lease agreement square feet | SquareFeet | 41,195 | |||||
Lease completion of building initial term | 12 years | |||||
Lease payments | $ 118,000 | |||||
Design costs | 2,120,000 | $ 2,120,000 | ||||
Design costs expense | 580,000 | 580,000 | ||||
Budget remaining | 2,700,000 | 2,700,000 | ||||
Receivables project | 0 | 0 | ||||
Payables project | $ 0 | $ 0 | ||||
University of South Dakota Research Park Inc [Member] | Maximum [Member] | ||||||
Defined Benefit Plan Disclosure [Line Items] | ||||||
Pre construction costs | $ 2,700,000 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) | 3 Months Ended | 9 Months Ended | ||||||
Oct. 26, 2022 | Oct. 11, 2022 USD ($) ft² | Oct. 05, 2022 $ / shares | Oct. 01, 2022 USD ($) $ / shares | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | |
Subsequent Event [Line Items] | ||||||||
Rent due on annual basis | $ 309,000 | $ 285,000 | $ 930,000 | $ 836,000 | ||||
Sanford Health [Member] | ||||||||
Subsequent Event [Line Items] | ||||||||
Rent due on annual basis | $ 15,000 | $ 93,000 | ||||||
Subsequent Event [Member] | ||||||||
Subsequent Event [Line Items] | ||||||||
Closing bid price of common stock, minimum requirement | $ / shares | $ 1 | |||||||
Number of consecutive business days | 30 days | |||||||
Initial compliance period | 180 days | |||||||
Initial compliance date | Apr. 03, 2023 | |||||||
Subsequent Event [Member] | Manufacturing Agreement [Member] | ||||||||
Subsequent Event [Line Items] | ||||||||
Minimum notice period for first commercial manufacturing needs | 24 months | |||||||
Minimum notice period for each additional product | 12 months | |||||||
Notice period for intent to exercise manufacturing option | 60 days | |||||||
Subsequent Event [Member] | Sanford Health [Member] | Fourth Amendment to Amended and Restated Lease Agreement [Member] | ||||||||
Subsequent Event [Line Items] | ||||||||
Area of property leased | ft² | 21,014 | |||||||
Rent due on annual basis | $ 531,024 | |||||||
Rent due on monthly basis | $ 44,252 | |||||||
Subsequent Event [Member] | October Note [Member] | Sanford Health [Member] | ||||||||
Subsequent Event [Line Items] | ||||||||
Interest rate | 8% | |||||||
Debt instrument, principal amount | $ 541,644 | |||||||
Debt instrument, maturity date | Sep. 30, 2024 | |||||||
Debt instrument, conversion price per share | $ / shares | $ 1.50 | |||||||
Subsequent Event [Member] | Minimum [Member] | ||||||||
Subsequent Event [Line Items] | ||||||||
Closing bid price of common stock, minimum requirement | $ / shares | $ 1 | |||||||
Number of consecutive business days | 10 days |